Introduction {#s1}
============

Hematopoiesis, the development of different blood cell lineages from hematopoietic stem cells (HSCs), is a fundamental physiological process in vertebrates. HSCs give rise to lineage-restricted progenitors that gradually differentiate into mature cells. Following cellular differentiation, single-lineage elements including erythrocytes, megakaryocytes, lymphocytes as well as myeloid cells such as monocytes and granulocytes circulate throughout the body performing diverse functions. While HSC development towards cellular lineages during homeostasis has been extensively studied ([@bib34]), the mechanisms by which how progenitors give rise to mature cells during stress responses are less comprehended. For instance, certain pathogens regulate production of blood cells by the bone marrow and it has been shown that fine-tuned regulation of cytokine-induced signals is required for differentiation of HSC into mature cell types ([@bib40]; [@bib54]; [@bib87]). For example, the protozoan parasite that causes kalazar, *Leishmania donovani,* inhabits the bone marrow of humans ([@bib42]), targets bone marrow stromal macrophages ([@bib20]) and induces differentiation of myeloid cells at the expense of lymphoid progenitors ([@bib1]; [@bib20]). In the same line of evidence, after experimental exposure to Gram-negative bacteria, mice display increased amounts of bone marrow-derived neutrophils, through a G-CSF--C/EBPα dependent mechanism ([@bib14]). Moreover, infection by intracellular bacteria has been shown to modulate production of circulating leukocytes involving IFN-γ-mediated pathways ([@bib10]; [@bib47]; [@bib56]). Altogether, these studies indicate vertebrate hosts respond to infection by 'remodeling' cell lineage production, which are highly dependent upon the interplay of cytokine-induced hematopoiesis triggered during infection. Interestingly, recent reports have demonstrated hematopoietic stem/progenitor cells (HSPCs) may be infected by different classes of infectious agents such as viruses and bacteria, albeit at low efficiency ([@bib18]; [@bib41]). Therefore, since many pathogens may reach the bone marrow and provide microbial-HSC interactions, it is possible that, in addition to cytokines, pathogen recognition by progenitor cells directly regulate cell lineage commitment providing an anti-microbial defense system. In contrast, the Red Queen hypothesis ([@bib79]) predicts such pathogens would benefit from cell lineage commitment to establish themselves into the host.

The human pathogen *Mycobacterium tuberculosis* (*Mtb*) has been recently detected in circulating HSCs (Lin^-^CD34^+^) from latent TB individuals ([@bib77]). Since *Mtb* can also gain access to the bone marrow during extra-pulmonary ([@bib53]) as well as active pulmonary TB ([@bib22]), it has been suggested that the human bone marrow is a niche/reservoir for this bacterium during natural pathogen infection. However, whether interactions between *Mtb* and human CD34^+^ cells drive cellular differentiation has not been formally demonstrated. Interestingly, earlier ([@bib70]; [@bib72]) and recent ([@bib12]; [@bib83]) studies have reported major changes in the peripheral myeloid cells such as increased blood counts and dysregulated 'interferon transcriptional signature' during active TB. More specifically, several 'interferon-stimulated genes' (ISGs) are modulated in circulating mature neutrophils and monocytes in active TB patients, which calls forth a possible role of such genes in TB pathogenesis ([@bib12]; [@bib25]; [@bib83]). In contrast, lymphocyte compartments were recently demonstrated to be contracted during progression from latent to active TB in humans ([@bib73]). Therefore, the observed changes in blood leukocytes could be a consequence of the interactions between Mtb and the bone marrow cellular environment. Thus, we hypothesized that *Mtb* regulates cellular differentiation of human HSPCs. By employing in vitro functional assays and integrated systems biology analysis of published available cohorts of healthy controls and TB patients, our study suggests that *Mtb* co-opts an evolutionarily recent IFN/IL-6/CEBP axis linking monocyte differentiation and disease severity.

Results {#s2}
=======

*Mtb* H37Rv replicates in primary human CD34^+^ cell cultures {#s2-1}
-------------------------------------------------------------

To investigate the dynamics of *Mtb* infection by HSPCs, we have exposed peripheral blood mononuclear cells (PBMCs) from healthy donors to H37Rv *Mtb* (multiplicity of infection, MOI3) and measured bacterial infectivity by CD34^+^ cells. First, by using a fluorescent dye (syto-24) which does not influence bacteria infectivity (data not shown), flow cytometry experiments demonstrated that *Mtb* were associated with CD34^+^ cells following 4 hr exposure to mycobacteria ([Figure 1a,b](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). At that time point, we observed \~69% of CD34^+^ and \~79% of CD14^+^ associated with *Mtb* ([Figure 1c](#fig1){ref-type="fig"}). When compared to CD14^+^ cells, which are highly phagocytic cells, the MFI measurements within the CD34^+^ cell population were found to be \~4 x lower ([Figure 1d](#fig1){ref-type="fig"}). These data suggest that PBMC CD34^+^ cells may be permissive to *Mtb* infection in vitro. Similarly, purified cord blood derived CD34^+^ cells display comparable % and MFI as those seen in PBMC CD34^+^ cells ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}). Confocal microscopy analysis confirmed the presence of sparse intracellular mycobacteria in purified cord blood derived CD34^+^ cells at 4 hr post-infection (pi) ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). These findings raise the possibility that although human primary Lin^-^CD34^+^ cells can be infected by *Mtb* in vitro and in vivo ([@bib77]), this cell population may display intrinsic resistance to *Mtb* infection as it has been reported for other bacterial species ([@bib41]). Next, we employed a purified cell culture system to investigate whether H37RV *Mtb* replicates in CD34^+^ cells in different time points. When sorted purified cord-blood CD34^+^ cells were exposed to *Mtb* H37Rv (MOI3) and cultivated in StemSpan SFEM II ([@bib13]; [@bib39]), bacilli numbers exhibited a \~ 1.5 log growth at 5 days post infection (dpi) ([Figure 1e](#fig1){ref-type="fig"}). As a control, purified CD14^+^ cells displayed higher bacterial proliferation than purified CD34^+^ cells over time ([Figure 1](#fig1){ref-type="fig"}-[Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}). Together, these findings demonstrate that *Mtb* infects and replicates in primary human CD34^+^ cell cultures in vitro. While at one dpi bacilli were more associated with the surface of round cells ([Figure 1f](#fig1){ref-type="fig"}), at five dpi intracellular bacteria were associated with cells with abundant cytoplasm ([Figure 1f](#fig1){ref-type="fig"}), suggesting that *Mtb*-exposed cultures displayed increased frequencies of cells exhibiting morphological alterations over time ([Figure 1f](#fig1){ref-type="fig"}, right panel). Indeed, Giemsa staining ([Figure 1g](#fig1){ref-type="fig"}, arrows) presented higher frequency of cytoplasm- richer cells in bacteria-exposed vs uninfected cell cultures ([Figure 1g](#fig1){ref-type="fig"}, right panel), thus suggesting that *Mtb* infection enhances cellular differentiation by CD34^+^ cells in vitro.

![*Mtb* H37Rv infects human CD34^+^ cells and proliferates in cell cultures in vitro.\
PBMC from healthy donors were exposed to syto24-labeled *Mtb* H37Rv (MOI3, [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}) for 4 hr. (**a**) Representative flow cytometry contour plots of gating strategy to analyze *Mtb* syto24 association in FVS-negative (live) CD34^+^ events and CD14^+^ events. (**b**) Live CD34^+^Lin^-^ events gated in a were analyzed for *Mtb*-Syto24 MFI. Black line: Uninfected control. Blue, orange and purple lines represent samples from three different donors. (**c**) Frequencies and (**d**) MFI of *Mtb* syto24^+^ events in CD34^+^ or CD14^+^ events gates from uninfected or *Mtb* syto24-exposed bulk PBMCs. Results are means ± SEM of data pooled from three independent experiments, n = 10 healthy donors. \*\*\*p≤0.001 between *Mtb* syto24 CD34^+^ vs CD14^+^ groups. (**e,**) Purified cord blood-derived CD34^+^ cells were exposed to *Mtb* H37Rv (MOI3) for different time points and CFUs from cell culture lysates were enumerated in 7H10 media. Results are means ± SEM of data pooled from five independent experiments, \*\*\*p≤0.001 between 5d vs 4 hr groups. (**f**) Kinyoun staining of CD34^+^ cells after 1d and 5d of infection and quantification, as described in the methodology section, shown in the right panel. Arrows indicate cells associated with bacilli. Experiments shown are representative of two performed. \*\*p≤0.01 between 5d vs 1d groups. (**g**) Representative Giemsa staining of CD34^+^ cells of 5d-cultures and quantification, as described in the methodology section, shown in the right panel. Arrow indicates cytoplasm-rich cells in *Mtb*-infected cultures and uninfected cultures. Experiments shown are representative of two performed. \*p≤0.05 between *Mtb* vs uninfected groups.\
10.7554/eLife.47013.005Figure 1---source data 1.Raw data from [Figure 1](#fig1){ref-type="fig"}.](elife-47013-fig1){#fig1}

Live *Mtb* induces CD34^+^ cells towards myeloid differentiation and monocyte output {#s2-2}
------------------------------------------------------------------------------------

Next, to investigate whether *Mtb* triggered cellular differentiation by human CD34^+^ cells, we evaluated differential expression of 180 transcription factors (TFs) associated with differentiation of distinct hematopoietic cells ([@bib60]) in RNA-seq samples of *Mtb*-exposed purified cells ([Figure 1---figure supplement 1e](#fig1s1){ref-type="fig"} -- [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Interestingly, *Mtb* infection increased the expression of lineage-specific regulators of myeloid (GRAN/MONO) (*SPI1, CEBPB, CEBPA, EGR2 and STAT2*), but not lymphoid (B and T CELL) (*GABPA, SOX5, TCF3, GATA3, LEF1, RORA and LMO7*) or megakaryoid/erythroid (EARLY/LATE ERY) (*GATA1, FOXO3, NFE2, TAL1*) differentiation ([Figure 2a](#fig2){ref-type="fig"} -- [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Similarly, CellRouter ([@bib46]) signature score of the GRAN/MONO gene set was found to be increased in *Mtb* vs uninfected samples in all time points studied ([Figure 2b](#fig2){ref-type="fig"} - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Next, we applied a network biology-built computational platform ([@bib17]) which, based on classification scores, can assess the extent to which a given population resembles mature cell types. [Figure 2c](#fig2){ref-type="fig"} ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}) shows that mRNA samples from *Mtb*-exposed CD34^+^ cells presented enrichment of monocyte/macrophage profiles, but not other mature cell populations such as lymphocytes or dendritic cells. Additionally, at five dpi, CD34^+^ cell cultures displayed increased frequencies of cells positive for CD11b ([Figure 2d](#fig2){ref-type="fig"}), a surface molecule expressed during myeloid differentiation ([@bib32]; [@bib71]). Together, these data suggest that *Mtb* drives human primary CD34^+^ cells towards myeloid differentiation. We next employed flow cytometry to measure cell surface molecules previously associated with myeloid differentiation of human CD34^+^ cells ([@bib19]; [@bib28]; [@bib38]; [@bib50]; [@bib63]). More specifically, we gated on CD34^+^ events and quantified % CD64^+^CD4^+^ cells. Corroborating our hypothesis, *Mtb* enhanced the frequency of CD64^+^CD4^+^CD34^+^ cells ([Figure 2e--h](#fig2){ref-type="fig"}) at five dpi, but not CD10^+^CD34^+^ (lymphoid) or CD41a^+^CD34^+^ (megakaryoid) progenitors ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). Similarly, Lin^-^CD34^+^ cells from PBMC ([Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}) samples from healthy donors exposed to *Mtb* displayed increased frequency of CD4^+^CD64^+^CD34^+^ cells and augmented levels of CD38 and HLA-DR ([Figure 2---figure supplement 1b,c](#fig2s1){ref-type="fig"}), two molecules associated with advanced stage of cellular differentiation ([@bib19]; [@bib24]; [@bib76]). When compared to their base line levels, we also observed an increased % CD4^+^CD64^+^CD34^+^ cells in *Mtb*-exposed bulk bone marrow samples from two healthy individuals ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}, p=0.08). In addition, frequencies of CD4^+^CD64^+^CD34^+^ cells were higher in cultures infected to live H37Rv *Mtb* than those exposed to heat-killed (HK) bacteria ([Figure 2f,g](#fig2){ref-type="fig"}). These results suggest that the observed cellular phenotype was mostly due to the activities of live pathogen and only partially to mycobacterial PAMPs such as TLR2 (Ara-LAM) or TLR9 (*Mtb* gDNA) agonists ([@bib7]; [@bib78]), which induced CD38 and HLA-DR, but not CD4 and CD64 expression in CD34^+^ cells ([Figure 2---figure supplement 1d](#fig2s1){ref-type="fig"}). Importantly, increased frequency of CD4^+^CD64^+^CD34^+^ cells was also observed when cell cultures were exposed to a clinical isolate of *Mtb* ([Figure 2h](#fig2){ref-type="fig"}), ruling out a possible genetic factor associated with the laboratory strain H37Rv ([@bib15]). Furthermore, CD34^+^ cell death was not enhanced by *Mtb* infection as demonstrated by the use of a live-and-dead probe and lactate dehydrogenase (LDH) quantification in cell culture supernatants ([Figure 2---figure supplement 1e,f](#fig2s1){ref-type="fig"}). Together, these data indicate live *Mtb* directs primary human CD34^+^ cells towards myeloid differentiation in vitro.

![Live *Mtb* induces human CD34^+^ cells towards myeloid differentiation in vitro.\
Purified CD34^+^ cells from healthy donors (n = 3) were exposed to *Mtb* H37Rv (MOI3) for different time points and mRNA-seq was performed as described in methodology section. (**a**) Heatmap of the mRNA expression (z-score) of transcription factors involved in cell lineage commitment ([@bib60]). (**b**) Signature score of data from **a**) by employing CellRouter analysis. (**c**) Heatmap from mRNA data of uninfected vs *Mtb* infected cultures analyzed by CellNet. (**d**) Purified CD34^+^ cells were exposed to *Mtb* H37Rv (MOI3) for 5 days and flow cytometry was performed. Graph represents frequencies of CD11b^+^ events in uninfected (open circles) vs *Mtb-*infected cultures (blue circles) from four independent experiments. \*\*p≤0.01 between *Mtb* and uninfected groups. (**e**) Purified CD34^+^ cells were exposed to *Mtb* H37Rv, Heat-killed (HK) *Mtb* H37Rv or *Mtb* clinical isolate 267 (*Mtb*-CS267) (MOI3) for 5 days and flow cytometry with the gating strategy was performed. (**f**) Representative contour plots show frequencies of CD4^+^CD64^+^ events in CD34^+^ events. CD34^+^CD4^+^CD64^+^ events of polled data from **f**) were plotted to generate bar graphs (**g**) and (**h**). Results are means ± SEM of data pooled from four independent experiments (**g**) and two independent experiments (**h**). (**g**) \*\* indicates p≤0.01 between H37Rv vs uninfected or HK H37RV groups. (**h**) \* indicates p≤0.05 between *Mtb*-CS267 vs uninfected groups.\
10.7554/eLife.47013.009Figure 2---source data 1.Raw data from [Figure 2](#fig2){ref-type="fig"}.\
10.7554/eLife.47013.010Figure 2---source data 2.Counts matrix of RNAseq data of *Mtb*-exposed and control CD34+ cell transcriptomes.](elife-47013-fig2){#fig2}

Next, to investigate whether *Mtb* enhanced HSPC differentiation into mature myeloid populations ([@bib38]; [@bib43]; [@bib50]), purified CD34^+^ cells were exposed to *Mtb* and 10d later, surface molecules were measured by flow cytometry. Live H37Rv ([Figure 3a,e](#fig3){ref-type="fig"}) or clinical isolate *Mtb*, ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}) but not *Leishmania infantum* promastigotes (data not shown), enhanced expression of the monocyte surface molecule CD14, confirming the observed monocyte/macrophage output enrichment by CellNet analysis ([Figure 2c](#fig2){ref-type="fig"}). Interestingly, in this in vitro culture system, CD14^+^ cells started to emerge at low levels at day three in both uninfected and *Mtb*-exposed cell cultures, while enhancement in monocyte frequency was observed in *Mtb*-stimulated cells at later time points, that is at 7 and 10 dpi. ([Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Compared to control cell cultures, CD14^+^ cells induced by *Mtb* displayed similar MFI expression of CD11b, HLA-DR, CD64 and CD16 surface molecules ([Figure 3i](#fig3){ref-type="fig"}) and most, but not all experiments presented increased frequency of CD14^+^CD16^+^ monocytes ([Figure 3j](#fig3){ref-type="fig"}), which were previously associated with severe pulmonary TB ([@bib9]). Moreover, albeit not statistically significant, *Mtb* enhanced the frequency of CD16^+^CD66b^+^ neutrophils in the majority but not all samples tested ([Figure 3b,f](#fig3){ref-type="fig"}). In contrast, HK *Mtb* did not stimulate monocyte or neutrophil output ([Figure 3e,f](#fig3){ref-type="fig"}). As expected ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}), megakaryoid/platelet- ([Figure 3c,g](#fig3){ref-type="fig"}), dendritic cell- ([Figure 3d,h](#fig3){ref-type="fig"}) or erythroid- ([Figure 3---figure supplement 1c](#fig3s1){ref-type="fig"}) associated markers were unchanged after exposure to live or HK *Mtb*. Altogether, these results suggest *Mtb* selectively favors the generation of monocytes and, to a lesser extent, neutrophils, by human CD34^+^ cells in vitro.

![*Mtb* infection increases monocyte output from CD34^+^ cells in vitro.\
Purified CD34^+^ cells were exposed to live *Mtb* H37Rv or HK *Mtb* H37Rv (MOI3) for 10 days and flow cytometry was employed to determine the mature cell frequencies in the cell cultures. Representative dot plots of (**a**) monocytes (CD14^+^), (**b**) neutrophils (CD16^+^CD66b^+^), (**c**) megakaryocytes/platelets (CD41a^+^) and (**d**) classical myeloid dendritic cells (BDCA1^+^CD14^low^) in uninfected and *Mtb*-infected CD34^+^ cell cultures. Graphs show frequencies of (**e**) CD14^+^, (**f**) CD16^+^CD66b^+^, (**g**) CD41a^+^ and (**h**) BDCA1^+^CD14^low^ events in uninfected (open circles), live *Mtb*-infected (blue diamonds) or HK *Mtb*-exposed (red diamonds) cell cultures at day 10. Each symbol represents one individual experiment. Results are means ± SEM of data pooled from 3 to 9 independent experiments. \*\*p≤0.01 between *Mtb* vs uninfected or HK *Mtb* groups. (**i,**) Histograms show the expression of CD11b, HLA-DR, CD64 and CD16 in CD14^+^ events from **a**). Black dashed lines: Uninfected control. Blue solid lines: *Mtb*-infected group. Data representative of 5 independent experiments. (**j,**) Frequency of CD14^+^CD16^+^ events in *Mtb*-exposed cell cultures after 10d. Contour dot plot of CD14^+^CD16^+^ frequencies from one representative donor. Open circles: Uninfected control. Blue circles: *Mtb*-infected group. Each symbol represents an individual experiment. Pooled data of eight independent experiments, n = 5 different donors. p=0.076 between *Mtb* vs uninfected groups.\
10.7554/eLife.47013.014Figure 3---source data 1.Raw data from [Figure 3](#fig3){ref-type="fig"}.](elife-47013-fig3){#fig3}

In vitro *Mtb*-enhanced myeloid differentiation is mediated by IL-6R, but not type I or type II IFN signaling {#s2-3}
-------------------------------------------------------------------------------------------------------------

Cytokines are important triggers of Lin^-^CD34^+^ differentiation in vivo and in vitro ([@bib27]; [@bib34]; [@bib87]) and Reactome pathway analysis of genes differentially expressed between *Mtb*-infected versus uninfected conditions displayed enrichment of 'cytokine signaling in immune system' ([Figure 3---figure supplement 1d](#fig3s1){ref-type="fig"}; n = 3 donors, two independent experiments - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Among several genes, we observed a significant enrichment of *IL6* ([Supplementary file 1](#supp1){ref-type="supplementary-material"} - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), a key HSPC-derived regulator of myeloid differentiation in mouse and human models ([@bib35]; [@bib88]) which was confirmed in our system by the addition of exogenous IL-6 to CD34^+^ cells ([Figure 4---figure supplement 1a](#fig4s1){ref-type="fig"}). Moreover, cytokine receptors, including *IL6R*, as well as their cytokine partners, containing *IL6*, were enriched in *Mtb*-exposed CD34^+^ cell cultures ([Figure 4a,b](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1b](#fig4s1){ref-type="fig"} - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Similarly, increased *IL6* expression was confirmed by qPCR ([Figure 4---figure supplement 1c](#fig4s1){ref-type="fig"}). In addition, 'interferon signaling' and 'interferon alpha/beta' pathways were significantly enriched in *Mtb*-exposed CD34^+^ cells ([Figure 3---figure supplement 1d](#fig3s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). This was confirmed in five donors, which displayed increased levels of *IFNA2*, *IFNB* and *IFNG* transcripts, albeit at a lower level relative to *IL6* mRNA ([Figure 4---figure supplement 1c](#fig4s1){ref-type="fig"}). Importantly, interferon-stimulated genes (ISGs) such as *MX1*, *ISG15* and *IFI16* as well as IL-6R-stimulated genes such as *IL1RA*, *GRB2* and *CXCL8* were enhanced in *Mtb*-stimulated CD34^+^ cells from five different donors ([Figure 4---figure supplement 1d](#fig4s1){ref-type="fig"}), suggesting IL-6 and IFN signaling are active in these cells. Corroborating previous findings showing that HSPCs produce IL-6 following microbial stimuli ([@bib3]), live *Mtb* also induced intracellular IL-6 production in Lin^-^CD34^+^ cells from bacteria-exposed PBMC 1d cultures ([Figure 4c](#fig4){ref-type="fig"}). This was confirmed in 1d culture supernatants of purified CD34^+^ cells exposed to live *Mtb* which presented augmented levels of IL-6, but not IFN-γ, IL-1β or TNF ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}). Interestingly, while HK *Mtb* also stimulated production of IL-6 ([Figure 4c](#fig4){ref-type="fig"}), dead bacteria did not induce CD38, CD4 and CD64 expression in PBMC Lin-CD34^+^ cells as seen in cell cultures exposed to live *Mtb* ([Figure 4---figure supplement 1f](#fig4s1){ref-type="fig"}). When compared to the live pathogen, qPCR experiments with HK *Mtb*-exposed purified CD34^+^ cells did not show induction of ISG *STAT1* ([Figure 4---figure supplement 1g](#fig4s1){ref-type="fig"}), suggesting the existence of cross talking regulatory pathways between live *Mtb*, IL-6 and IFN signaling to boost myeloid differentiation in vitro. Since these data pointed that IL-6 and IFN signaling are potential pathways involved in *Mtb*-enhanced myeloid differentiation by CD34^+^ cells, we employed neutralizing monoclonal antibodies as a tool to investigate this possibility. While type I IFN signaling was necessary for *Mtb*-stimulated ISGs such as *STAT1* and *MX1* transcription ([Figure 4---figure supplement 1h](#fig4s1){ref-type="fig"}), neither type I nor type II IFN signaling pathways were required for *Mtb*-enhanced monocyte/granulocyte conversion ([Figure 4d,e](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1i](#fig4s1){ref-type="fig"}). In contrast, neutralizing anti-IL-6Ra antibody (α-IL-6R) inhibited background levels of CD14^+^ monocytes and CD66b^+^ granulocytes, as well as *Mtb*-enhanced myeloid differentiation by CD34^+^ cell cultures ([Figure 4f--h](#fig4){ref-type="fig"}) but not transcription of *STAT1* and *MX1* ([Figure 4---figure supplement 1h](#fig4s1){ref-type="fig"}). In addition, megakaryoid, erythroid- or dendritic cell-associated surface molecules were unaltered in α-IL-6R-treated cell cultures ([Figure 4---figure supplement 1j--l](#fig4s1){ref-type="fig"}). Interestingly, *Mtb*-exposed CD34^+^ cell cultures treated with α-IL-6R ([Figure 4i](#fig4){ref-type="fig"}) presented significantly lower CFU counts when compared with infected untreated control cell cultures, while α-IFNAR2 ([Figure 4j](#fig4){ref-type="fig"}) or α-IFN-γ ([Figure 4k](#fig4){ref-type="fig"}) did not affect CFU counts. Together, these results suggest live *Mtb* enhances IL-6R-mediated myeloid differentiation by human CD34^+^ cells in vitro.

![*Mtb* enhances IL-6R-mediated myeloid differentiation in vitro.\
Purified CD34^+^ cells were exposed to *Mtb* H37Rv (MOI3) for different time points and mRNA-seq was performed as described in the methodology section. (**a**) Heatmap (z-score) of differentially expressed cytokine receptor genes. (**b**) Heatmap (z-score) of differentially expressed cytokine genes. Shown is the average mRNA expression of three different donors from two independent experiments. (**c**) PBMC from healthy donors were exposed to Mtb H37Rv, HK Mtb or LPS (100 ng/mL) for 24 hr and intracellular IL-6 was detected by flow cytometry. Live CD34+Lin- events gated as in [Figure 1a](#fig1){ref-type="fig"} were analyzed for IL-6 MFI. Representative histogram from two independent experiments. Purified CD34^+^ cells were treated with (**d**) α-IFNAR2 (1 µg/ml) or (**e**) α-IFN-γ (10 µg/ml) and then exposed to *Mtb* H37Rv (MOI3) during 10d for determination of CD14^+^ monocyte frequencies. Results are means ± SEM of data pooled from two independent experiments. \*p≤0.05 between *Mtb*, α-IFNAR2 or α-IFN-γ vs uninfected groups. (**f**) Representative contour plots of CD14^+^ monocytes in CD34^+^ cell cultures exposed to *Mtb*, in the presence or absence of α-IL6R (Tocilizumab, 1 µg/ml) for 10d. (**g**) Results shown are means ± SEM of data pooled from three independent experiments from (**f**) \*\*p≤0.01 between *Mtb* vs uninfected groups and \#p≤0.05 between *Mtb* and *Mtb*+α-IL6R-treated groups. (**h**) Results shown are means ± SEM of data pooled from three independent experiments showing frequency of CD66^+^CD16^+^ neutrophils in *Mtb*-infected cell cultures in the presence or absence of α-IL6R. Purified CD34^+^ cell cultures were treated as in (**d--f**) with (**i**) α-IL6R, (**j**) α -IFNAR2 and (**k**) α-IFN-γ and then exposed to *Mtb* (MOI3) for different time points and CFU enumerated as described in the methodology section. Results are means ± SEM of data pooled from four independent experiments. \*\*p≤0.01 between *Mtb* and *Mtb*+ α-IL6R at 7d.\
10.7554/eLife.47013.018Figure 4---source data 1.Raw data from [Figure 4](#fig4){ref-type="fig"}.](elife-47013-fig4){#fig4}

An *IL6/IL6R/CEBPB* gene module is enriched in the active TB transcriptome and proteome {#s2-4}
---------------------------------------------------------------------------------------

To investigate whether IL-6R signaling correlates with monocyte expansion and TB-associated pathology in vivo, we performed a comprehensive systems biology analysis integrating several large transcriptomic and proteomic data sets from published cohorts of healthy controls and patients with latent, active and disseminated TB ([@bib12]; [@bib31]; [@bib58]; [@bib61]; [@bib73]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). First, we used Ingenuity Pathway analysis (IPA) to determine IL-6/IL-6R upstream regulators in transcriptomes from publicly available CD14^+^ monocytes of active TB patients ([@bib12]).. As shown in [Figure 5a](#fig5){ref-type="fig"} (top panel), *IL6, IL6ST, IL6R* and *STAT3* were significantly enriched in transcriptomes of active TB monocytes, when compared to cells from healthy controls. As reported previously ([@bib12]; [@bib51]; [@bib61]), *STAT1* and *IL1B* were also confirmed as upstream regulators in active TB monocytes ([Figure 5a](#fig5){ref-type="fig"}, top panel). We next examined potential genes share between IL6/IL6R and type I IFN signaling pathways in active TB monocytes. Strikingly, the two top upstream regulators in TB monocytes, *IRF1* and *STAT1* ([Figure 5a](#fig5){ref-type="fig"}, top panel), were the only genes in common between the TB monocyte gene signature ([@bib12]), the 'IL6/STAT3 pathway' and the 'in vivo IFN-β" signature ([Figure 5a](#fig5){ref-type="fig"}, Venn diagram, bottom panel), suggesting these genes might be regulated by both IL-6 and type I IFN during active TB in vivo. Since type I IFN and IL-6 share the ability to induce phosphorylation of both STAT1 and STAT3 ([@bib33]), we ran gene set enrichment analysis (GSEA) ([@bib75]) to identify potential overlapping downstream target genes in the whole blood 'Berry TB' disease signature ([@bib12]). In addition to the previously demonstrated type I IFN/STAT1 signature ([@bib12]), the 'IL6/STAT3' pathway was significantly enriched in this data set (FDR-corrected p\<10^−4^, [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Next, we defined protein signatures by overlapping the 'Berry TB', the 'IL6/STAT3' pathway with a published plasma proteome defining disease progression from latent to active TB ([@bib73]) ('Scriba Plasma TB', [Figure 5b](#fig5){ref-type="fig"}, Venn Diagram top panel). STRING network analysis of protein-protein interactions confirmed two clusters ([Figure 5b](#fig5){ref-type="fig"}, bottom panel), which comprised three signatures: 'CD34/myeloid', 'IL6/STAT3' and 'IFN/IL6-shared' pathways. Reanalysis of the published 'Scriba Plasma TB' proteome set ([@bib73]) confirmed increased IL-6/STAT3 protein levels and changes in CD34/CD38 homeostasis, which were found to be early events in TB pathogenesis ([Figure 5c](#fig5){ref-type="fig"}, top panel). 'IL6/STAT3' pathway-associated proteins such as PLA2G2A, CRP, STAT3, IL-6 and CFB increased around 12 months before TB diagnosis ([Figure 5c,d](#fig5){ref-type="fig"}, top panels - orange circles and bars), which was concomitant with significant changes in the 'IFN/IL6-shared' plasma markers CXCL10, IFNAR1 and MMP9 ([Figure 5c,d](#fig5){ref-type="fig"} top panels - blue circles and bars). The 'IL6/STAT3' and 'IFN/IL6-shared"pathways were also significantly enriched in a gene set recently linked to monocyte expansion in vivo, measured as monocyte:lymphocyte (ML) ratio ([@bib58]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), and positively correlated with mycobacterial growth in vitro, thus connecting monocyte expansion and increased *Mtb* survival. Interestingly, the changes found in both the 'IL6/STAT3' and 'IFN/IL6-shared' pathways during development of TB disease preceded enrichment of the 'ML ratio' gene set ([@bib58]) (6 months before diagnosis, p\<0.05, [Figure 5c](#fig5){ref-type="fig"}, bottom panel and [Figure 5d](#fig5){ref-type="fig"}, top panel, gray bar) and reduction of the CD34/CD38 gene markers, in agreement with our in vitro model of *Mtb*-enhanced CD34^+^ differentiation (CD34^+^ → CD34^+^CD38^+^ → CD14^+^). Moreover, fold changes were higher for 'IL6/STAT3' pathway genes than for 'IFN/IL6-shared' genes, and significantly higher than 'ML ratio' genes (p\<0.05) or 'CD34/myeloid' differentiation genes (p\<0.01) ([Figure 5d](#fig5){ref-type="fig"} bottom panel). Together, these data suggest sequential activation of IL-6/IL-6R and IFN signaling pathways before monocyte expansion during TB disease progression in vivo, raising a possible link between these two events in disease pathogenesis. In support of this idea, CD34^+^ cells exposed to *Mtb* in vitro displayed increased levels of pSTAT1 as well as C/EBPβ (and a slight enhancement of C/EBPα), which are key TF regulators of ISGs and myeloid differentiation genes, respectively ([Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}). Interestingly, qPCR experiments from HK *Mtb*-exposed CD34^+^ cells did not show induction of myeloid differentiation TFs *CEBPA* and *CEBPB* ([Figure 4---figure supplement 1g](#fig4s1){ref-type="fig"}). Furthermore, we observed that *CEBPB, CEBPD and STAT3* as well as *IRF1*, *STAT1 and ICSBP/IRF8* TFs were significantly enriched in *Mtb*-infected CD34^+^ transcriptomes ([Figure 5e](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1b](#fig5s1){ref-type="fig"} - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), which were associated with increased mycobacterial replication in vitro ([Figure 1e](#fig1){ref-type="fig"}). These results suggest that *Mtb* infection activates a gene module shared by both type I IFN and IL-6, linking downstream ISGs and CEBPs.

![*IL6/IL6R/CEBPB* gene module is enriched in active TB transcriptome and proteome and correlates with monocyte expansion.\
(**a**) Top panel: upstream regulators significantly enriched by causal Ingenuity Pathway Analysis (IPA) in monocyte transcriptomes from patients with active TB (GSE19443), ranked by activation z-score, p-values are corrected for genome-wide testing (FDR). Bottom panel: IRF1 and STAT1 are the top upstream regulators shared between the 'Berry TB' disease signature ([@bib12]) (GSE19435, GSE19439, GSE19444), the 'IL6/STAT3' pathway (Hallmark GSEA) and the human 'in vivo IFN-β" signature (GSEA HECKER_IFNB1_TARGETS). (**b**) Top panel: overlap between the 'Berry TB' disease signature, the 'IL6/STAT3' pathway and the 'Scriba plasma TB' proteomic signature ([@bib73]) identified 'IFN/IL6-shared' and 'IL6/STAT3-specific' signatures. Bottom panel: significant STRING protein-protein interaction network (p\<10^−16^) for 'IFN/IL6-shared' genes (green marbles) and 'IL6/STAT3' genes (red marbles), clustering separately by k-means. (**c**) Top panel: significant linear increase over time before active TB diagnosis in plasma proteome ([@bib73]) for 'CD34/myeloid' (yellow), 'IL6/STAT3' (orange) and 'IFN/IL6-shared' (blue) clusters found in (**b**). Bottom panel: monocyte/lymphocyte (ML) ratio gene set members defined by [@bib58] over time before active TB diagnosis in plasma proteome ([@bib73]).(**d**) Top panel: increased 'IL6/STAT3' cluster protein expression precedes monocyte expansion markers (ML ratio gene set) in the TB plasma proteome. Bottom panel: data as in **d**) shows significant higher fold-changes for 'IL6/STAT3' vs. 'ML ratio' or 'CD34/myeloid' cluster members. \*p-value\<0.05, \*\* p-value\<0.01. (**e**) Transcription factor enrichment analysis (GSEA) of differentially expressed genes determined by RNA-seq in *Mtb*-exposed CD34^+^ cells in vitro (n = 3 donors). (**f**), monocyte count and ML ratio in samples from latent vs active TB patients from [@bib12] reanalysis. \*p-value\<0.05, \*\* p-value\<0.01 between active TB vs latent TB groups. Transcriptional data of whole blood reanalysis from [@bib12] shows a significant correlation of *CEBPB* transcripts with **g**) M/L ratio; **h**) *IL6R*; **i**) *STAT3* transcript levels, and **j**) mycobacterial positivity in sputum smears in patients with active TB. \*\* p-value\<0.01 between positive vs negative groups.\
10.7554/eLife.47013.021Figure 5---source data 1.Raw data from [Figure 5](#fig5){ref-type="fig"}.](elife-47013-fig5){#fig5}

An *IL6/IL6R/CEBP* gene module correlates with monocyte expansion and TB severity {#s2-5}
---------------------------------------------------------------------------------

TB pathogenesis is a convoluted process which interconnects mycobacterial dissemination, host inflammatory responses and systemic tissue pathology. To further investigate a potential link between this gene module (*IL6/IL6R/CEBP*) with disease severity and monocyte expansion in vivo, we first examined large transcriptomic data sets of 'disseminated TB', which includes extrapulmonary and lymph node TB (GSE63548). The 'IL6/STAT3' pathway was found to be significantly enriched among differentially expressed genes in both extrapulmonary (FDR p=10^−3^) and lymph node TB (FDR p=10^−4^, [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Furthermore, downstream targets of *STAT3*, *CEBPB, CEBPD, SPI1*/*PU1, ICSBP/IRF8,* which are TF regulators of myeloid differentiation, were enriched in 'disseminated TB' and in the 'ML ratio' gene sets ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), suggesting these TFs are activated during severe disease and associated to monocyte expansion in vivo. In contrast, ISRE (STAT1/STAT2) and IRF1 motifs, the major upstream regulators observed in TB monocyte transcriptome ([Figure 5a](#fig5){ref-type="fig"} top panel) and shared between IL-6 and IFN signaling ([Figure 5b](#fig5){ref-type="fig"}), were not enriched in the 'ML ratio' gene set ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Of note, only *CEBPB* targets were significantly enriched in the 'ML ratio' gene set in healthy subjects ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), supporting its link with myeloid differentiation during homeostasis. Since the *IL6/IL6R/CEBP* gene module was correlated with both systemic disease dissemination and monocyte expansion, two processes associated with TB disease ([@bib70]; [@bib72]), we next examined whether these genes might be connected to disease severity in a published cohort with detailed clinical parameters and transcriptome data ([@bib12]). When compared to latent TB subjects, we observed that both the monocyte counts and ML ratio were significantly increased in active TB patients ([Figure 5f](#fig5){ref-type="fig"}). *CEBPB* transcripts positively correlated with ML ratio levels ([Figure 5g](#fig5){ref-type="fig"}), *IL6R* transcripts ([Figure 5h](#fig5){ref-type="fig"}), *STAT3* ([Figure 5i](#fig5){ref-type="fig"}) as well as inflammatory biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) ([Figure 5---figure supplement 1c](#fig5s1){ref-type="fig"}). In addition, *CEBPB* mRNA levels were significantly higher in *Mtb*-positive vs. *Mtb*-negative sputum smears ([Figure 5j](#fig5){ref-type="fig"}), and positively correlated to tissue damage, total symptom counts as well as *ISG15* levels ([Figure 5---figure supplement 1c](#fig5s1){ref-type="fig"}), in agreement with our previous findings ([@bib25]). Taken together, these results indicate that the *IL6/IL6R/CEBP* gene module is a hub correlated with monocyte expansion during *Mtb* infection in vivo and is amplified in severe pulmonary and systemic disease.

Recent mammalian/primate genetic changes link an IFN/IL-6/IL-6R/CEBP axis to monocyte expansion and TB pathogenesis in humans {#s2-6}
-----------------------------------------------------------------------------------------------------------------------------

The 'type I IFN' signature found in active TB ([@bib12]), shared with the IL-6/IL-6R-regulated gene set ([Figure 5](#fig5){ref-type="fig"}), comprises a number of well-characterized ISGs with cross-species antiviral activity such as *IRF1* and *OAS*. It has been reported that these ISGs have been undergoing strong purifying selection during primate evolution ([@bib49]; [@bib74]), including recent Neanderthal introgression ([@bib26]; [@bib67]). We thus undertook an evolutionary approach to investigate whether the *IL6/IL6R/CEBP* gene module and its partial overlap with type I IFN signaling is linked to monocyte expansion and TB severity. To do so, we performed a stepwise analysis, starting from early mammalian emergence (\>100 million years ago (mya), over primate (\>50 mya) and hominid evolution (\>15 mya). We have also examined the recent human evolution including Neanderthal introgression (\<100,000 years ago) and human pathogen adaptation (15,000--1,500 years ago), up to extant human genetic variation through analysis of large genome wide association studies (GWAS).

First, STRING network measurements of amino acid conservation and gene co-occurrence across mammalian and primate evolution revealed that IL-6, IL-6R and C/EBP family members C/EBPα, C/EBPβ and C/EBPδ differ substantially throughout primate evolution and even among closely related hominins (*Pan troglodytes* and *Gorilla gorilla*) ([Figure 6a](#fig6){ref-type="fig"}, heat map). In contrast, matched control molecules in the same STRING network (KLF5/NFKB1/MAPK1//STAT1*/*STAT3) remained largely conserved in most mammals, and even in birds and reptiles ([Figure 6a](#fig6){ref-type="fig"}, heat map and [Figure 5---figure supplement 1d](#fig5s1){ref-type="fig"}). Next, to investigate the biological consequence of the evolutionary differences in overlapping IL-6/IFN signaling, we reanalyzed cross-species type I IFN regulation from the 'mammalian interferome' database ([@bib74]). As expected, the conserved 'IFN/IL6-shared' genes *CXCL10/CXCL9/STAT1/STAT2* displayed higher fold-changes upon type I IFN treatment across all 10 species (from chicken to human, [Figure 6b](#fig6){ref-type="fig"}, top panel). Interestingly, the 'IL-6/STAT3' pathway genes *IL6, STAT3* and *SOCS3* were also significantly upregulated while *IL6R* was significantly down-regulated ([Figure 6b](#fig6){ref-type="fig"}, top panel) in the same experimental setting. Among CD34/myeloid differentiation genes, *ICSBP/IRF8* and *CD38* were strongly upregulated, but only in 4/10 and 2/10 species, respectively, while *ELF1* was homogeneously and significantly upregulated in 9/10 species ([Figure 6b](#fig6){ref-type="fig"}, top panel). These results suggest that type I IFN consistently regulates expression of IL-6 signaling and myeloid-associated genes in different species. However, among the entire *IL6/IL6R/CEBP* myeloid gene set, *CEBPB* was the topmost variable ISG across mammalian evolution (CV \>1000%, [Figure 6b](#fig6){ref-type="fig"}, bottom panel). Remarkably, type I IFN-induced upregulation of both *CEBPB* and *CEBPD*, previously identified as NF-IL6 and NF-IL6β, respectively ([@bib68]) was present only in humans and lacking in all other mammals investigated ([Figure 6b](#fig6){ref-type="fig"}, bottom panel, inset). Mechanistically, ChipSeq analysis of IFN-treated human CD14^+^ monocytes corresponding to regions with active chromatin (DNase Hypersensitivity Sites, DHS and H3K27 acetylation, not shown) confirmed the existence of functional STAT1 peaks in *CEBPB* and *CEBPD* ([Figure 6c](#fig6){ref-type="fig"}, top and middle panels, denoted by vertical blue lines). These peaks correlated with increased downstream transcription in CD14^+^ cells, as compared to purified CD34^+^ cells ([Figure 6c](#fig6){ref-type="fig"}, RNA-seq). In agreement with our findings (represented in [Figure 6b](#fig6){ref-type="fig"}, bottom panel, *inset*), only 3 out of 11 (27%) STAT1 binding peaks in *CEBPB* and *CEBPD* were found in conserved regions (Conservation Birds-Mammals line, [Figure 6c](#fig6){ref-type="fig"}), while 6 out of 7 (86%) STAT1 peaks were conserved in *CXCL9* and *CXCL10* genes ([Figure 6c](#fig6){ref-type="fig"}, bottom panel). Interestingly, transcriptional regulation of *CEBPB* and *CEBPD* in humans and macaques, but not mouse cells stimulated with double-stranded RNA, which mimics a viral infection ([Figure 6---figure supplement 1a](#fig6s1){ref-type="fig"}), were also observed in an independent data set ([@bib30]). As expected, *CXCL9* and *CXCL10* responses are conserved in dsRNA-stimulated cells from humans, macaques and mouse ([Figure 6---figure supplement 1a](#fig6s1){ref-type="fig"}). Thus, transcriptional induction of *CEBPB* and *CEBPD* controlled by IL-6- and type I IFN-signaling appears as a relatively recent event in mammalian and primate evolution.

![Evolutionary recent and human-specific genetic adaptation link *IL6/IL6R/CEBP* gene module with monocyte expansion and TB pathogenesis.\
(**a**) Heat map showing *CEBPB* network generated by STRING co-occurrence protein conservation scores across primates, mammals, birds and reptiles. Note only *CEBPB and CEBPA* differ strongly among hominids, while *CEBPA/CEBPB/CEBPD* vary significantly throughout primate and mammalian evolution, as compared to highly conserved *STAT1/STAT3* ([Figure 5---figure supplement 1d](#fig5s1){ref-type="fig"}). (**b**) Top panel: Highly conserved type I IFN upregulation of 'IFN/IL6-shared' genes from humans to birds (derived from <http://isg.data.cvr.ac.uk/>) ([@bib74]), as compared to 'IL6/STAT3' and 'CD34/myeloid differentiation' genes. Bottom panel: *CEBPB* and *CEBPD* displays highest variation, and *CXCL10* the lowest variation in type I IFN transcriptional regulation across human-mammalian-bird evolution. *Inset, CEBPB* and *CEBPD* selectively acquired type I IFN upregulation in humans (filled circles); \*\* p-value\<0.01 and \* p-value\<0.05 represent *CEBPB* and *CEBPD* values, respectively for humans versus the other species. (**c**) ChipSeq analysis of STAT1-binding peaks in *CEBPD* (top panel), *CEBPB* (middle panel), *CXCL9* and *CXCL10* (bottom panel) in IFN-stimulated human monocytes, corresponding to regions with active chromatin (DNase Hypersensitivity Sites, DHS) and correlating with increased downstream transcription in CD14^+^ monocytes, as compared to purified CD34^+^ cells. Conservation analysis among \>40 vertebrates (phyloP \[[@bib65]\], from chicken to human, analogous to [Figure 5b](#fig5){ref-type="fig"}) indicates STAT1 peaks are mostly conserved in *CXCL9/CXCL10* (6/7) but not in *CEBPD/CEBPB* (3/11). (**d**) Top panel: overlap between human genes with significant Neanderthal introgression ([@bib26]; [@bib67]), genes differentially expressed in *Mtb*-exposed CD34^+^ cells (CD34^+^ Mtb UP) and the 'ML ratio' gene set. Bottom left panel: *OAS1, OAS2* and *MT2A* transcripts presented significantly higher effect sizes upon ML ratios, corresponding to monocyte expansion, as compared to other introgressed genes (p\<0.05) and to all other genes shown to regulate ML ratio in vivo (p\<0.001). Bottom right panel: normalized expression of introgressed genes found in CD34^+^Mtb UP (Venn diagram) in TLR1/2 agonist-treated monocytes from a cohort of matched Belgian individuals of European (EUB) vs. African (AFB) descendance, with documented presence or absence of Neanderthal introgression ([@bib67]), respectively. p-value\<0.05, \*\* p-value\<0.01, \*\*\* p-value\<0.001, \*\*\*\* p-value\<0.0001.\
10.7554/eLife.47013.025Figure 6---source data 1.Raw data from [Figure 6](#fig6){ref-type="fig"}.](elife-47013-fig6){#fig6}

Genome-wide association studies (GWAS) connect the *IL6/IL6R/CEBP* gene module with monocyte expansion in TB disease {#s2-7}
--------------------------------------------------------------------------------------------------------------------

Since genetic susceptibility and transcriptional responses to intracellular pathogens have shown significant links to Neanderthal introgression in populations of European and Asian descent ([@bib21]; [@bib67]), we next explored enrichment for introgression in the *IL6/IL6R/CEBPB* and 'ML ratio' gene sets. As shown in [Figure 6d](#fig6){ref-type="fig"} ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), eleven genes with Neanderthal introgression were significantly upregulated in our *Mtb-*exposed CD34^+^ cells transcriptome (enrichment p\<0.0001). Of those, *OAS1, OAS2* and *MT2A* transcripts had significantly higher effect sizes upon ML ratios, as compared to other introgressed genes (p\<0.05) and to all other genes shown to regulate ML ratio in vivo (p\<0.001, [Figure 6d](#fig6){ref-type="fig"}). This finding was confirmed in a recently published data set (n = 198) of purified microbial-exposed CD14^+^ monocytes from a Belgian cohort of European (EUB) and African (AFB) descendance, with documented presence or absence of Neanderthal introgression, respectively ([@bib67]). Strikingly, 9 out of 11 introgressed genes enriched during *Mtb*-triggered monocyte differentiation ([Figure 6d](#fig6){ref-type="fig"}, Venn diagram) were significantly upregulated in TLR1/TLR2-stimulated ([Figure 6d](#fig6){ref-type="fig"}, right panel), but not unstimulated monocytes (not shown). These findings suggest pathogen exposure may enhance gene pathways recently selected during hominid evolution linked to monocyte expansion.

We next interrogated whether the *IL6/IL6R/CEBP* gene module was linked with monocyte expansion in several large published data sets of standing human variation. Two large GWAS studies ([@bib6]; [@bib37]) containing \>230,000 individuals have identified single-nucleotide polymorphisms (SNPs) in or adjacent to *IL6R, CEBPA-CEBPD-CEBPE* and *ICSBP/IRF8* genes as significantly associated to blood monocyte counts ([Supplementary file 2](#supp2){ref-type="supplementary-material"} and ranked in [Figure 7a](#fig7){ref-type="fig"} as monocyte count GWAS). Moreover, gene-specific z-scores for human polygenic adaptation to pathogens in 51 different populations worldwide ([@bib23]) were positive, representing higher levels of population differentiation, for all genes in our proposed *IL6/IL6R/CEBP* myeloid differentiation module (except *CXCL10,* [Figure 7a](#fig7){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). Lastly, we examined whether myeloid differentiation genes identified in this study are found in GWAS TB susceptibility genes. A significant enrichment (p\<0.0001) for differentially expressed genes from our *Mtb*-exposed CD34^+^ transcriptome and TB susceptibility GWAS/candidate genes (18 out of 172 genes, including *IL6, STAT1* and *CD14)* was also observed ([Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}). Similarly, a significant (p\<0.0001) overlap was found for the *IL6/IL6R/CEPB* module and TB genetic susceptibility (six shared genes *CD14, CXCL10, IL6, IL6R, IRF1* and *STAT1*, [Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}).

![Compiled multi-level evidence for an *IL6/IL6R/CEBP* gene module linking CD34^+^ myeloid differentiation to TB pathogenesis and disease severity.\
(**a**) Ranks and scores were determined as 0--1 (presence-absence in data set) or 0-1-2-3, according to enrichment analysis or differential gene expression (quartiles); z-scores were obtained from Daub et al.^55 ^(**b**) Proposed model for C/EBPβ and C/EBPδ acting as a bridge in the type I IFN and IL-6 feed-forward loop exploited by *Mtb* to induce monocyte differentiation and TB disease severity (details in the text).\
10.7554/eLife.47013.027Figure 7---source data 1.Raw data from [Figure 7](#fig7){ref-type="fig"}.](elife-47013-fig7){#fig7}

As ranked in [Figure 7a](#fig7){ref-type="fig"}, 24 out of 28 members of this gene module display a genome-wide, transcriptomic, proteomic or functional association to human TB, being strongest for *IL6* and its downstream signaling TFs *CEBPB* and *CEBPD*, demonstrated in 5--6 independent data sets each. Collectively, our multi-level-based evidence suggests *Mtb* exploits an evolutionary recent IFN/IL-6/IL-6R/CEBP axis linked to monocyte expansion and human TB disease.

Discussion {#s3}
==========

Emerging evidence has suggested that *Mtb* establishes an infectious niche in the human bone marrow during active TB, which is associated with altered numbers of leukocytes in the periphery ([@bib22]; [@bib53]; [@bib58]; [@bib70]; [@bib72]; [@bib77]; [@bib81]). In the present study, we observed that *Mtb* consistently stimulated myeloid differentiation molecules in CD34^+^ cell cultures from three different human tissues, namely: bone marrow, peripheral blood or cord blood samples. Employing a purified cord-blood-derived CD34^+^ culture cell system, we observed that *Mtb* enhances IL-6R-mediated myeloid differentiation by human primary CD34^+^ cells in vitro. Importantly, IL-6/IL-6R downstream molecules such as C/EBPβ, C/EBPδ, STAT3 and their targets were significantly enriched in cell transcriptomes from active TB patients as well as were positively correlated with disease severity. Therefore, our data expands previous studies and raise a scenario in which *Mtb* skews myeloid development, mediated by IL-6/IL-6R signaling, as a key step in human TB pathogenesis.

While *Mtb* enhanced *IL6* expression in purified CD34^+^ cell cultures from all donors, *IFNA* and *IFNB* mRNA were detected in some but not all donors. However, ISGs were highly enriched in the bacteria-exposed samples suggesting that although low/undetectable amounts of type I IFN were produced in infected cell cultures ([@bib69]), these cytokines were present in the cell culture ([Figure 4---figure supplement 1h](#fig4s1){ref-type="fig"}). Furthermore, our results show that live *Mtb* is a potent stimulus to induce ISGs ([Figure 6---figure supplement 1c](#fig6s1){ref-type="fig"} - [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}) and myeloid differentiation in primary human CD34^+^ cells. However, while heat killed mycobacteria induced IL-6 production by CD34^+^ cells, it poorly stimulated *STAT1*, *CEBPB* and differentiation cell surface molecules by progenitor cells as well as CD14^+^ monocyte levels. Interestingly, although IL-6R signaling was involved in both myeloid differentiation and *Mtb* growth by CD34^+^ cell cultures, type I or type II IFN signaling were not. These results suggest that monocyte maturation is connected to *Mtb* proliferation in vitro and could explain why the effects of anti-IL6R antibodies on cellular differentiation inhibited bacteria growth ([Figure 4f--i](#fig4){ref-type="fig"}). Although the ISG gene set was enriched in *Mtb*-exposed CD34^+^ cells, our data suggest type I or type II IFN signaling appear not to mediate *Mtb*-enhanced monocyte development in vitro. Collectively, this evidence suggests that unknown activities of live pathogen infection regulate myeloid differentiation involving an IL-6R-mediated process and implies cross-talking of regulatory pathways between live *Mtb*, IL-6 and IFN signaling to boost myeloid differentiation of CD34^+^ cells. At the molecular level, it has been reported that IFN-induced C/EBPβ triggers gamma-activated transcriptional elements (GATE) sequences independent of STAT1 ([@bib44]), suggesting the existence of cooperative and/or redundant roles of IL-6 and IFN signaling in different molecular settings. The mechanisms by which endogenous IL-6, IFN-α/β and live *Mtb* interplay to enhance C/EBP-mediated myeloid differentiation of HSPCs require further investigation. Of note, in our previously characterized cohort of multiple sclerosis patients ([@bib52]; [@bib80]), IFN-β therapy in vivo did not significantly change monocyte or lymphocyte counts, nor did it increase the ML ratio after three months of treatment in patients with documented clinical response (data not shown), supporting the idea that type I IFN by itself is not sufficient to cause monocyte expansion in vivo.

It has not been determined how mature myeloid cell populations from active TB patients acquire the 'ISG' signature. While monocytes and other cells may encounter *Mtb*-associated inflammatory stimuli in infected tissues (e.g. lungs and liver), our data suggest the possibility that *Mtb* may activate these cells during their development in the bone marrow. We have not directly addressed whether circulating monocytes/granulocytes acquire their phenotype in the bone marrow, during development of myeloid progenitors in vivo. Nevertheless, a recent study by [@bib59] demonstrated increased monocyte egress from the bone marrow in a murine model of *Mtb* infection. Considering mycobacteria ([@bib5]; [@bib22]; [@bib36]; [@bib53]; [@bib55]) can access the bone marrow and stimulate IL-6, it is possible that individuals draining higher amounts of *Mtb* into the bone marrow display increased inflammatory alterations including IL-6R-mediated myelopoiesis, upregulation of IFN-stimulated responses and amplified disease severity. Likewise, we found that enrichment of the *IL6/IL6R/CEBP* axis positively correlated with systemic disease such as lymph node and extrapulmonary TB ([Figure 5f,g](#fig5){ref-type="fig"}).

Several independent studies have also indicated a detrimental role of 'IFN and IFN-induced genes' during *Mtb* infection in human TB ([@bib12]; [@bib16]; [@bib25]; [@bib61]; [@bib73]; [@bib86]) and murine models ([@bib4]; [@bib48]). Our results expand these previous studies, revealing a novel *IL6/IL6R/CEBP* gene module and its link to monocyte development, mycobacterial dissemination and TB disease severity. Furthermore, as evidenced by [@bib73] and re-analyzed in the present study ([Figure 5c,d](#fig5){ref-type="fig"}), both IFN and IL6 pathways are early events in TB pathogenesis, detectable in the plasma proteome \>6 months before diagnosis. Nevertheless, a pivotal role for IL6/IL6R signaling has not been evident from previous 'omics' approaches. While IL-6 signaling partially overlaps with type I IFN responses ([Figure 5a,b](#fig5){ref-type="fig"}), possibly due to their shared ability to activate STAT1 and STAT3 ([@bib33]), whole blood transcriptomic analyses in TB are predominated by an 'IFN-inducible neutrophil signature' ([@bib12]). Therefore, the high numbers of neutrophils in the blood possibly mask differential expression of other gene sets in less frequent populations, such as monocytes, monocyte subsets and, in particular, Lin^-^CD34^+^ cells.

Most ISGs present in the whole blood Berry TB signature ([@bib12]), the Scriba TB plasma proteome ([@bib73]) and the Naranbhai et al. ML ratio gene set ([@bib58]) displayed cross-species type I IFN-induction throughout mammalian evolution ([Figure 6b](#fig6){ref-type="fig"}). Despite a shared STAT1/STAT3 activation by type I IFN and IL-6, homeostatic activation of C/EBPβ is mostly IL-6-specific, as evidenced by data mining and STRING analysis ([Figure 6a](#fig6){ref-type="fig"}), in keeping with its original description as NF-IL6 ([@bib2]). Across species, *CEBPB* and *CEBPD* are among the highly variable ISG of the entire IFN/IL-6/CD34/myeloid gene set ([Figure 6b](#fig6){ref-type="fig"}). Likewise, although type I IFN-induced *IL6* and *STAT3* transcription are conserved in all mammalian species studied, IFN-inducibility of *CEBPB* and *CEBPD* mRNA appeared to be recently acquired in primate evolution. In line with our observations, *IL6*, *CEBPB* and *SPI1/PU1* genetic polymorphisms have been previously associated with TB susceptibility ([@bib85]; [@bib84]). In addition, a recently identified *trans* e-QTL (rs5743618) ([@bib67]) in *TLR1*, a gene with peak Neanderthal introgression ([@bib21]; [@bib26]; [@bib30]; [@bib67]) has been associated to TB susceptibility in several populations worldwide ([@bib11]; [@bib57]; [@bib66]). Biological pathway analysis of genes significantly regulated in trans of rs5743618 revealed a significant enrichment of IL-6/STAT3 signaling and *IL6* as the most connected gene (data not shown). In agreement, *Mtb-*induced macrophage IL-6 production, among other cytokines, can be predicted on the basis of strong genetic components as recently reported by [@bib8] in a large GWAS/immunophenotyping cohort study. By employing a data-driven multi-level analysis from large cohorts, we expand these previous observations and revealed significant genetic links shared between IL-6/IL-6R/CEBP signaling, CD34^+^ myeloid differentiation, monocyte homeostasis and TB susceptibility (compiled in [Figure 7a](#fig7){ref-type="fig"}). Together, these findings favor the hypothesis that such genetic changes have undergone stepwise mammalian, primate and recent human selection, including Neanderthal introgression and worldwide population-specific pathogen adaptation.

In summary, our observations suggest that *Mtb* boosts myeloid differentiation by exploiting a feed-forward loop between IL-6 and type I IFN molecular networks, bridged by C/EBPβ (and C/EBPδ) ([Figure 7b](#fig7){ref-type="fig"}). Yet, further experiments will define the precise mechanisms of crosstalk between IFN, IL-6 and CEBP family members, specifically CEBPβ and CEBPδ, during natural *Mtb* infection. While this question merits direct investigation, nonetheless, the use of IL-6R blockade as an adjunct therapy to treat multi-drug resistant severe TB has been proposed ([@bib62]; [@bib89]). Thus, the present study provides evidence of a novel host-directed target for therapeutic intervention in a major human disease.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                           Designation                                                                                                                       Source or\                     Identifiers                                                                    Additional\
  (species) or\                                                                                                                                                             reference                                                                                                     information
  resources                                                                                                                                                                                                                                                                               
  --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------
  Strain (*Mycobacterium tuberculosis*)   H37Rv                                                                                                                             ATCC                                                                                                          

  Strain (*Mycobacterium tuberculosis*)   Mtb-CS267                                                                                                                         Clinical Isolate               This study                                                                     

  Cell Line (*Homo sapiens*)              Human Cord Blood (CB) purified CD34^+^ cells                                                                                      STEMCELL Technologies          Catalog\#70008.5                                                               Cell line maintained in StemSpan II Expansion Media - STEMCELL Technologies- Catalog\#09605

  Cell (*Homo sapiens*)                   Peripheral blood mononuclear cell (PBMC)                                                                                                                                                                                                        Cells maintened in RPMI 1640 complete, Sigma-Aldrich -- Catalog\#R8758

  Chemical Compound, drug                 Middlebrook 7H10 agar                                                                                                             BD Biosciences                 Catalog\# 262710                                                               Supplemented with 10% Oleic Acid,Albumin, Dextrose, Catalase (Sigma-Aldrich -- Catalog\# M0678-1VL)

  Chemical Compound, drug                 L-Glutamine (200 mM)                                                                                                              Sigma-Aldrich                  Catalog\# 25030081                                                             

  Chemical Compound, drug                 Sodium Pyruvate (100 mM)                                                                                                          Life Technologies.             Catalog\# 11360070                                                             

  Biological Sample                       Genomic DNA, *Mycobacterium tuberculosis*, Strain H37Rv                                                                           This study                                                                                                    Dosage: 10 μg/ml

  Chemical Compound, drug                 *Mycobacterium tuberculosis*, Strain H37Rv, Purified Lipoarabinomannan (LAM)                                                      BEI Resources                  Catalog\# NR-14848                                                             Dosage: 5 µg/mL

  Peptide, Recombinant protein            Recombinant Human Interleukin 6 (rh IL-)                                                                                          ImmunoTools                    Catalog\# 11340064                                                             

  Antibody                                FITC Anti-Lineage 1, human: CD3 clone SK7, CD16 clone 3G8, CD19 clone SJ25C1, CD20 clone L27, CD14 clone MφP9, CD56 clone NCAM.   BD Biosciences                 Catalog\# 340546                                                               (1:30)

  Antibody                                PE Anti-human CD34, clone 581.                                                                                                    BD Biosciences                 Catalog\# 555822                                                               (1:20)

  Antibody                                FITC Anti-human CD34, clone 8G12.                                                                                                 BD Biosciences                 Catalog\#\                                                                     (1:50)
                                                                                                                                                                                                           345801                                                                         

  Antibody                                PerCP Anti-human CD34, clone 581.                                                                                                 Biolegend                      Catalog\# 343519                                                               (1:20)

  Antibody                                PECy7 Anti-human HLA-DR, clone L243                                                                                               Biolegend                      Catalog\# 307615                                                               (1:200)

  Antibody                                Bv510 Mouse Anti-Human HLA-DR, clone G46-6                                                                                        BD Horizon                     Catalog\# 563083                                                               (1:100)

  Antibody                                APC Anti-human CD38, clone HIT2                                                                                                   Biolegend                      Catalog\# 303510                                                               (1:100)
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Reagents {#s4-1}
--------

*Mtb* Ara-LAM was obtained from BEI Resources and used at 5 µg/mL. *Mtb* H37Rv genomic DNA was obtained from 28 days colonies growing in Löwenstein--Jensen medium by CTAB method as previously described ([@bib82]). Recombinant human (*rh)* IL-6 was purchased from Immunotools. Anti-IFNAR2A (clone MMHAR-2, PBL) and anti-IFN-γ (clone B27, Immunotools) neutralizing antibodies were used at 1 and 10 µg/mL, respectively and anti-IL-6R (Tocilizumab, Roche) was used at 1 µg/mL. Fluorescent dye Syto24 was obtained from Thermo Fisher Scientific.

Mycobacteria cultures {#s4-2}
---------------------

The virulent laboratory H37Rv *Mtb* strain and the clinical *Mtb* isolate (Mtb-CS267) were maintained in safety containment facilities at LACEN and UFSC as described elsewhere ([@bib82]). Briefly, *Mtb* was cultured in Löwenstein-Jensen medium (Laborclin) and incubated for 4 weeks at 37°C. Prior to use, bacterial suspensions were prepared by disruption in saline solution using sterile glass beads. Bacterial concentration was determined by a number 1 McFarland scale, corresponding to 3 × 10^8^ bacteria/mL.

Subjects samples, cells and *Mtb* infections {#s4-3}
--------------------------------------------

This study was approved by the institutional review boards of Universidade Federal de Santa Catarina and The University Hospital Prof. Polydoro Ernani de São Thiago (IRB\# 89894417.8.0000.0121). Informed consent was obtained from all subjects. Peripheral blood and bone marrow mononuclear cells were obtained using Ficoll-Paque (GE) in accordance with the manufacturer's instructions. Briefly, blood collected in lithium-heparin containing tubes was further diluted in saline solution 1:1 and added over one volume of Ficoll-Paque reagent. The gradient was centrifuged for 40 min at 400 x *g*, 20°C. The top serum fraction was carefully removed, the mononuclear fraction was harvested and washed once in a final volume of 50 mL of saline solution for 10 min at 400 x *g*, 20°C. Subsequently, cell pellet was suspended and washed twice with 20 mL of saline solution for 10 min at 200 x *g*, 20°C, to remove platelets. Cells were then suspended to the desired concentration in RPMI 1640 (Life Technologies) supplemented with 1% fresh complement inactivated (30 min at 56°C) autologous serum, 2 mM *L*-glutamine (Life Technologies), 1 mM sodium pyruvate (Life Technologies) and 25 mM HEPES (Life Technologies). Human Cord Blood (CB) purified CD34^+^ cells from five different donors were obtained from STEMCELL Technologies and resuspended in StemSpan Expansion Media -- SFEM II (STEMCELL Technologies) according to manufacturer's instruction. Optimal cell density for replication was 5 × 10^4^ CD34^+^ cell/mL. In a set of experiments, CD34+ cells were further enriched using a cell sorter (FACSMelody, BD). Following 4 days of expansion, cells were washed and diluted in SFEM II media without cytokine cocktail to the desired concentration. Culture purity was assessed by FACS and showed more than 90% of CD34^+^ events after expansion. For in vitro infection experiments, 1 McFarland scale was diluted in media to fit the desired multiplicity of infection (MOI). For each experiment, bacteria solution was plated in Middlebrook 7H10 agar (BD Biosciences) supplemented with 10% Oleic Acid Albumin Dextrose Complex (OADC) and incubated at 37°C to confirm initial bacteria input. In a set of experiments, 1 McFarland scale was incubated with 500 nM of Syto24 dye as described previously ([@bib82]). In some experiments, H37Rv *Mtb* was heat killed (HK) at 100°C for 30 min. *Leishmania infantum* promastigotes were kindly provide by Ms. Karime Mansur/UFSC and Dr. Patrícia Stoco/UFSC and used at MOI = 3. In cytokine/cytokine neutralizing experiments, cells were pretreated with anti-IFNAR2 (1 µg/mL), anti-IFN-γ (10 µg/mL) or anti-IL-6R (1 µg/mL) for 1 hr and exposed to *Mtb* (MOI3). Following different time points post-infection, cells were harvested and centrifuged at 400 x *g* for 10 min, 20°C. Supernatants were then stored at −20°C, cells washed once in sterile saline solution and lysed by using 200 µL of 0.05% Tween 80 solution (Vetec) in sterile saline. Cell lysates were diluted in several concentrations (10^−1^ to 10^−5^), plated onto Middlebrook 7H10 agar (BD Biosciences) supplemented with OADC 10% and incubated at 37°C. After 28 days, colony-forming units (CFU) were counted and the results were expressed graphically as CFU/mL.

Microscopy experiments {#s4-4}
----------------------

After different time points post-infection, cells were washed and fixed with PFA 2% overnight at 4°C. Subsequently, cells were washed with sterile water solution and adhered into coverslips by cytospin centrifugation. Samples were then fixed with methanol for 5 min, washed with sterile water and stained with carbol-fuchsin (Sigma) for 2 min. Samples were washed once with sterile water and counterstaining was done with methylene blue dye (Sigma) for 30 s. Coverslips were fixed in slides with Permount mounting medium (Sigma) and examined using Olympus BX40 microscope and digital camera Olympus DP72. Quantification was performed by enumeration of number of infected cells or "cytoplasm-rich cells, defined as cells bigger than 10 um and with approximately 2:1 cytoplasm/nucleus ratio. Cells were counted in at least 10 fields from two different experiments and plotted as % of events. Syto24-stained *Mtb* was visualized in CD34^+^ cells by using confocal fluorescence-equipped inverted phase contrast microscope and photographed with a digital imaging system camera. Briefly, 1 × 10^5^ CD34^+^ cells were seeded in 24-well plate and infected with *Mtb* syto24, MOI3, for 4 hr. Further, cells were washed, fixed with PFA 2% and adhered into coverslip by cytospin centrifugation. For nucleus visualization, cells were stained with Hoechst 33342 (Immunochemistry technologies) for 2 hr. Cells were after washed and mounted for analysis in Leica DMI6000 B confocal microscope.

Immunoblotting {#s4-5}
--------------

CD34^+^ cells were seeded at 3 × 10^5^ cells in 24-well plate and infected with *Mtb* (MOI3). After 5 days of infection, cells were centrifuged at 4°C, pellet was lysed using M-PER lysis buffer (Thermo Fisher Scientific) containing protease inhibitors (Complete, Mini Protease Inhibitor Tablets, Roche) and protein extracts were prepared according to manufacturer's instructions. For Western blot, 15 µg of total protein were separated and transferred to nitrocellulose difluoride 0.22 µm blotting membranes. Membranes were blocked for 1 hr with TBST containing 5% w/v BSA and subsequently washed three times with TBST for 5 min each wash. Further, membranes were then probed with anti-pSTAT1 Y701 1:1000 (M135 -- Abcam), anti-STAT1 1:1000 (SM1 -- Abcam), anti-C/EBPβ 1:250 (sc-150 -- Santa Cruz) or anti-β-actin 1:5000 (8226 -- Abcam) primary antibodies diluted in 5% w/v BSA, 0.1% tween 20 in TBS, at 4°C with gentle shaking overnight. Membranes were washed with TBST, incubated in secondary HRP-linked Ab for 2 hr at room temperature, washed and chemiluminescence developed using ECL substrate (Pierce). Relative expression was normalized with β-actin control and pixel area was calculated using ImageJ software.

Flow cytometry {#s4-6}
--------------

PBMC and bone marrow mononuclear cells were seeded at 5 × 10^5^ cells per well in a final volume of 200 µL. After 4 hr of resting at 37°C with 5% CO~2~, cells were infected with *Mtb* (MOI3) for 72 hr, unless indicated otherwise. Cells were detached from the plate by vigorous pipetting, centrifuged at 450 x *g* for 10 min and washed twice in saline solution and stained with fixable viability stain FVS V450 (BD Biosciences) at the concentration 1:1000 for 15 min at room temperature. Cells were then washed with FACS buffer (PBS supplemented with 1% BSA and 0.1% sodium azide) and incubated with 10% pooled AB human serum at 4°C for 15 min. The following antibodies were used in different combinations for staining:

Staining of human CD34^+^ in PBMC: anti-Lin1(CD3, CD14, CD16, CD19, CD20,CD56) (FITC, clones MφP9, NCAM 16, 3G8, SK7, L27, SJ25-C1), anti-CD34 (PE, PE, clone 581), anti-CD34 (FITC, 8G12), anti-CD34 (PerCP, clone 581), anti-HLA-DR (PE-Cy7, clone L243), anti-HLA-DR (Bv510, clone G46-6), anti-CD38 (APC, clone HIT2), anti-CD4 (APC-Cy7,GK1.5), anti-CD64 (Bv421, clone 10.1), anti-CD10 (FITC, clone HI10A), anti-CD14 (V450, clone MoP9), anti-CD14 (Alexa488, clone M5E2) were added at titrated determined concentration and incubated for 40 min at 4°C.

Staining of CB CD34^+^ cells: anti-CD34 (PE, clone 581), anti-CD11b (APCCy7, clone M1/70), anti-CD4 (APC-Cy7, clone GK1.5), anti-CD64, (Bv421, MoP9), anti-CD14 (V450, clone MoP9) anti-CD14 (Alexa488, clone M5E2), anti-CD66b (PE, clone G10F5), anti-BDCA1 (APC-Cy7, clone L161), anti-CD41a (FITC, clone 6C9), anti-BDCA2 (APC, clone 201A), anti-BDCA3 (Bv510, clone 1A4), anti-Clec9A (A700, clone FAB6049P), anti-CD123 (PE, clone 7G3), anti-CD16 (APC, clone 3G8) were added at titrated determined concentrations and incubated for 40 min at 4°C. In a set of experiments, PBMCs were exposed to live Mtb, HK Mtb or LPS (100 ng/mL) for 24 hr and the Golgi Plug protein transport inhibitor (BD Biosciences) was added for the last 6 hr according to manufacturer's instructions. Then, cells were surface stained with FITC-Lin (FITC-anti-CD3, Alexa Fluor 488-anti-CD14, FITC-anti-CD16, FITC-anti-CD19, FITC-anti-CD56) and PerCP/Cy5.5-anti-CD34, followed by permeabilization and PE-anti-IL-6 (clone 8C9) staining. All cells were subsequently washed with FACS buffer and resuspended in 2% PFA. Cells were acquired on BD FACS Verse with FACSuite software. Analysis were performed using FlowJo software v. 10.1 (TreeStar).

Real-time quantitative PCR {#s4-7}
--------------------------

Total RNA was extracted from CD34^+^ cells exposed or not with *Mtb*. RNA was extracted after 1, 3 and 5 days of infection using TRIzol reagent (Thermo) according to manufacturer's instruction. Using 1 µg of RNA, cDNA was produced with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and 2 µL of 1:8 diluted product was used to the quantitative PCR reaction in a final volume of 10 µL. qPCR reactions were performed using the primers for: *IFNA2A* F: 5'-TTGACCTTTGCTTTACTGGT-3', R: 5'-CACAAGGGCTGTATTTCT TC-3'. *IL6* F: 5'- CCACACAGACAGCCACTCAC-3', R: 5'-AGGTTGTTTTCTGCCAGTGC-3'. *IFNB* F: 5'- AAACTCATGAGCAGTCTGCA-3', R: 5'-AGGAGATCTTCAGTTTCGGAGG-3'. *IFNG* F: 5'- TCAGCTCTGCATCGTTTTGG-3', R: 5'-GTTTCCATTATCCGCTACATCTGAA-3'. *IFI16* F: 5'-ACTGAGTACAACAAAGCCATTTGA-3', R: 5'-TTGTGACATTGTCCTGTCCCCAC-3'. *MX1* F: 5'-ATCCTGGGATTTTGGGGCTT-3', R: 5'-CCGCTTGTCGCTGGTGTCG-3'. *ISG15* F: 5'-TCCTGGTGAGGAATAACAAGGG-3', R: 5'-CTCAGCCAGAACAGGTCGTC-3'. *CXCL8* F: 5'-GAGGTGATTGAGGTGGACCAC-3', R: 5'-CACACCTCTGCACCCAGTTT-3'. *IL1RA* F: 5'-ATGGAGGGAAGATGTGCCTGTC-3', R: 5'-GTCCTGCTTTCTGTTCTCGCTC-3'. *GRB2* F: 5'-GAAATGCTTAGCAAACAGCGGCA-3', R: 5'-TCCACTTCGGAGCACCTTGAAG-3'. *STAT1* F: 5'-ATGGCAGTCTGGCGGCTGAATT-3', R: 5'-CCAAACCAGGCTGGCACAATTG-3'. *CEBPA* F: 5'-TGGACAAGAACAGCAACGAGTA-3', R: 5'-ATTGTCACTGGTCAGCTCCAG-3'. *CEBPB* F: 5'-TGGGACCCAGCATGTCTC-3', R: 5'-TCCGCCTCGTAGTAGAAGTTG-3'.

RNA isolation and sequencing {#s4-8}
----------------------------

Total RNA from purified CB CD34^+^ cells exposed to *Mtb* in vitro was isolated using TRIzol LS (Invitrogen; 10296010). RNA-seq libraries were prepared using the Nugen Ovation Trio low input RNA Library Systems V2 (Nugen; 0507--08) according to the manufacturer's instructions by the Nucleomics Platform (VIB, Leuven, Belgium). Pooled libraries were sequenced as 150 bp, paired-end reads on an Illumina HiSeq 2500 using v4 chemistry.

RNA-seq data quality assessment and differential expression analyses {#s4-9}
--------------------------------------------------------------------

Illumina sequencing adapters and reads with Phred quality scores lower than 20 were removed with Trimmomatic (0.36). Trimmed reads were aligned to *H. sapiens* reference genome (hg38) by STAR (2.6.0 c). Aligned reads were mapped to genes using feature Counts from the Subread package (1.6.1). Genes with reads of less than three were removed. Library based normalization was used to transform raw counts to RPKM and further normalized using the edgeR TMM normalization (3.10.0). Data were then transformed using the limma voom function (3.36.2), prior to batch correction using ComBat (sva 3.28.0). Negative binomial and linear model-based methods were used for differential expression analysis, using packages edgeR and limma packages. Differentially expressed genes (DEGs) were calculated with t-statistics, moderated F-statistic, and log-odds of differential expression by empirical Bayes moderation of the standard errors ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

CellNet and CellRouter analysis {#s4-10}
-------------------------------

We applied CellNet to classify RNA-seq samples as previously described ([@bib17]). Raw RNA sequencing data files were used for CellNet analysis. We used R version 3.4.1, CellNet version 0.0.0.9000, Salmon ([@bib64]) version 0.8.2 and the corresponding index downloaded from the CellNet website. We used CellRouter ([@bib46]) to calculate signature scores for each sample based on cell-type specific transcriptional factors collected from literature. Specifically, for this analysis, we normalized raw counts by library size as implemented in the R package DESeq2 ([@bib45]). We then plotted the distributions of signature scores across experimental conditions. Moreover, we used CellRouter to identify genes preferentially expressed in each experimental condition and used those genes for Reactome pathways enrichment analysis using the Enrichr package version 1.0.

Systems biology analysis {#s4-11}
------------------------

Ingenuity Pathway Analysis (IPA) software was used to perform the initial pathway/function level analysis on genes determined to be differentially expressed in transcriptomic analysis (Ingenuity Systems, Red Wood City, CA). Uncorrected p-values and absolute fold-changes were used with cut-offs of p\<0.05 (monocyte transcriptomes from active TB patients) or p\<0.01 (differentially expressed genes in *Mtb*-exposed CD34^+^ cells and all publicly available datasets from GEO). Differentially expressed genes were sorted into gene networks and canonical pathways, and significantly overrepresented pathways and upstream regulators were identified. Additional pathway, GO (Gene Ontology) and transcription factor target enrichment analysis was performed using GSEA (Gene Set Enrichment Analysis, Broad Institute Molecular Signatures Database (MSigDB)) and WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). Gene sets from GO, Hallmark, KEGG pathways, WikiPathways and Pathway Commons databases, as well as transcription factor motifs, were considered overrepresented if their FDR-corrected p-value was \<0.05. To validate our compiled *IL6/IL6R/CEBP* and CD34^+^ myeloid differentiation gene modules, we used STRING (version 10.5) protein-protein interaction enrichment analysis ([www.string-db.org](http://www.string-db.org)), using the whole human genome as background. Principal component analysis, correlation matrices, unsupervised hierarchical (Eucledian distance) clustering were performed using XLSTAT and visualized using MORPHEUS (<https://software.broadinstitute.org/morpheus/>). Chipseq, active chromatin and transcriptional (RNAseq) data of CD14 and CD34+ cells were downloaded from ENCODE (<https://genome.ucsc.edu/ENCODE/>) and visualized using the UCSC browser ([@bib29]).

Data processing and statistical analyses {#s4-12}
----------------------------------------

Data derived from in vitro experiments was processed using GraphPad Prism six software and analyzed using unpaired *t* test, one-way ANOVA or two-way ANOVA according to the experimental settings. Data from experiments performed in triplicate are expressed as mean ± SEM. Non-parametric tests (Mann-Whitney, Spearman correlation) were used for clinical data (sputum bacillar load, modal X-ray grade, symptom count) and molecular data that were not normally distributed, Pearson correlation was used for molecular data with a normal distribution. A list of the statistics analysis methods used in each figure is available a supplementary file ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). Statistical significance was expressed as follows: \*p≤0.05, \*\*p≤0.01 and \*\*\*p≤0.001.
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\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"*M. tuberculosis* hijacks an evolutionary recent IFN-IL-6-CEBP axis linked to monocyte expansion and disease severity\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ruslan Medhzitov (Reviewer \#2).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Reviewers recognized that your manuscript provides interesting evidence illustrating that *Mycobacterium tuberculosis* is able to drive monocyte differentiation from human hematopoietic stem cells through the IL-6/CEBP axis. The evolutionary description of this process is also interesting. However, there are numerous problems with some of the data, both conceptual and technical, which were identified by the reviewers. Further, the establishment of causality is somewhat lacking.

Reviewer \#1:

Background: *M. tuberculosis* has been detected in the bone marrow -- suggestive of a possible niche for tubercle bacteria in active and latent TB. This observation also points towards a role for mycobacteria in driving differentiation of certain cell types from Hematopoietic stem cells (HSCs).

Key findings include:

1\) The demonstration of the ability of tubercle bacteria to replicate in Hematopoietic stem cell progenitors (HSCPs), in this case CD14^+^ and CD34^+^ cells.

2\) Transcriptional analysis of infected CD13^+^ cells indicated that *M. tuberculosis* infection drives these cells towards myeloid differentiation, further confirmed by flow cytometry. This observation was confirmed with cells from cord blood also.

3\) A role for IL6R was confirmed in this myeloid differentiation pathway, using a neutralizing antibody.

4\) By interrogating transcriptome data, the authors confirm that the IL6R-CEBP pathway is central in monocyte expansion.

5\) Comparative genomics and evolutionary analysis reveal that this pathway has been the subject of recent selection.

Major Concerns:

1\) Figure 1---figure supplement 1C is meant to indicate that low numbers of bacteria associate with CD34^+^ cells. However, there is no comparison with CD14^+^, no quantification no statistics. This figure does not have use as it stands. Similarly, with Figure 1---figure supplement 1D -- one assumes the control here would be uninfected cells? In this case, the statistical comparison shown is meaningless -- comparing the bacterial load in CD14^+^ cells versus CD34^+^ cells on one graph would be more useful. The authors indicate they are comparable -- but need to provide the data in a way that allows for this comparison.

2\) Figures 1 F and G need quantification, followed by statistical comparison.

3\) Figure 2---figure supplement 1B and C needs statistics, -- are the differences significant, -- if not the text needs to be revised to indicate this. This applies to all supplementary graphs, -- these should have statistics. If differences are not significant \"NS\" should be stated. Same with Figures in the main text.

4\) The comparative genomics/transcriptomics and evolutionary analysis is very dense, -- it needs to be simplified and presented in a clearer manner.

Reviewer \#2:

In this manuscript Delgobo et al. demonstrate a novel role for *Mtb* in driving monocyte differentiation from human hematopoietic stem cells via an IL-6/CEBP axis. In vitro studies show that *Mtb* replicates in human CD34^+^ cells, and causes upregulation of the monocyte marker CD14 as well as enrichment of genes associated with myeloid differentiation. This in vitro monocyte expansion is demonstrated to be IL-6 dependent and associated with STAT1 and CEBP signaling. IL-6 receptor blockade impairs CD14 upregulation in infected CD34^+^ cell and reduces CFU burden, suggesting that this differentiation pathway is advantageous for *Mtb*. Interestingly, analysis of the IL6/IL6R/CEBP signaling axis among different mammalian species suggested that coordinate regulation of CEBP by IL6 and type 1 IFN is a relatively recent event in mammalian evolution and seems restricted to primates. This is corroborated by in vitro experiments using infection of cells from 10 species. Overall, the authors demonstrate, with compelling mechanistic evidence, a role for *Mtb* in co-opting an evolutionarily recent signaling axis to support infection by driving monocyte differentiation. The evolutionary aspect of the study is particularly intriguing.

Reviewer \#3:

In this manuscript the authors\' study the mechanisms by which HSPC differentiation occurs following *Mtb* infection. The authors uncover a less studied role for IL-6/IL-6R signaling in driving HSPC commitment to myeloid differentiation and exacerbating TB disease. In particular, re-analysis of previously published transcriptomic, proteomic, and genetic datasets support their hypotheses. Addressing the below points will further improve the impact of the findings.

Major comments:

Figure 1B-D:

The authors show that approximately 60% of CD34^+^ cells stain positively for *Mtb* with syto24, but that each of these cells has a much lower *Mtb* syto24 MFI than similarly infected CD14^+^ cells. However, after 4h, both CD34^+^ and CD14^+^ cells have a very similar number of CFU/ml.

Is the rate of uptake/infectivity potentially different when the cells are isolated and infected in a homogeneous culture rather than infected as total PBMCs?

It would also be useful to see the uninfected control quantified and included in the flow analysis as well.

Figure 3:

The authors show that heat-killed *Mtb* is unable to stimulate the same increase in myeloid differentiation of CD34^+^ cells as live *Mtb*. However, they later show that it is a cytokine (IL-6) dependent phenomenon. Are the IL-6 levels induced by heat-killed *Mtb* significantly lower than live infection?

Figure 4:

Cytokine signaling is a known trigger for myeloid cell differentiation, and therefore the authors identify differential expression of IL-6 as a potential driver of the increased number of CD14^+^ cells induced by *Mtb* infection. However, despite seeing what appears to be a significant transcriptional increase of IL-6 at 5dpi, there is no correlating increase in protein at that time point. CD34^+^ cells infected with *Mtb* and treated with aIL6R for 10d develop a lower percentage of CD14^+^ cells than untreated infected cells, at a much later time point than when differences in IL-6 induction (either by protein or transcriptional data) are seen.

A time course showing IL-6 levels in culture (1,3,5,7,10dpi) as well as a time course showing when the CD14^+^ population begins to expand in the untreated *Mtb* infected cells would more support the idea that it is an IL-6-dependent expansion. Alternatively, the authors could consider only blocking IL-6R early, when there is a significant difference in protein levels, to determine if there is the same effect on myeloid expansion.

Additionally, despite making note that \"interferon signaling\" and \"interferon alpha/beta\" pathways were significantly enriched in the infecting cells, neither IFNa/b nor IFN-g are well represented in the RNAseq data that is shown, and these cytokines are also not measured at the protein level. Including this data would provide better support for the data represented in Figure 4D-E, where no changes are seen after IFNAR or IFN-g blockade. This is a particularly critical point for the authors\' later argument that transcription factors induced by both IFN and IL-6 are primarily being driven by IL-6 to induce myeloid differentiation.

The authors show in Figure 1F-G that *Mtb* is associated with cells undergoing morphological change. If exogenous IL-6 alone is sufficient to drive this myeloid differentiation, why would the cells actively infected with *Mtb* be the only cells showing signs of differentiation? The authors may want to consider additional discussion of this point.

Reviewer \#4:

This manuscript investigates relationships (in human cells) between tuberculosis infection, hematopoiesis and monocyte expansion, and IL-6 signaling. In many respects the authors are investigating an aspect of \'trained\' immunity or myeloid lineage \'remodeling\' in the bone marrow. There are many substantial problems with this manuscript; the main one being an emphasis on correlation rather than causation. The authors attempt to draw conclusions that are predominantly indirect in nature.

1\) That CD34^+^ cells can be infected in vitro does not mean it happens in vivo. The authors draw from other studies that argue that *M.tb* can get to the bone marrow. However, overall, there is no evidence that CD34^+^ cells are infected in vivo and if this would make any difference to myeloid output. The authors ignore older studies in this area (Goodell\'s *M. avium* Nature paper, Murray et al. Blood on the IFN-gamma KO mice infected with BCG).

2\) Results section. The authors draw a conclusion \"These results suggest M.tb hijacks IL-6R-mediated myeloid differentiation by human CD34^+^ cells in vivo\". There is no evidence of \"hijacking\" provided. Only that something happens to the IL-6 pathway, which is entirely expected if a cell is infected with an intracellular bacteria.

3\) Subsection "Recent genetic changes link IL6/IL6R/CEBP axis, monocyte expansion and TB pathogenesis in humans". Myeloid expansion. In this very long section, the authors propose a correlation between myeloid expansion and M.tb infection, including a lengthy analysis of Neanderthal genomics, which cannot be tested.

In summary, the authors\' model may or may not happen. The reliance on correlative studies means no firm conclusions can be drawn about the system at hand. While some leeway is warranted because it is a human-based study, the overall conclusions are not sufficiently substantiated.

10.7554/eLife.47013.045

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in eLife.
>
> Reviewers recognized that your manuscript provides interesting evidence illustrating that Mycobacterium tuberculosis is able to drive monocyte differentiation from human hematopoietic stem cells through the IL-6/CEBP axis. The evolutionary description of this process is also interesting. However, there are numerous problems with some of the data, both conceptual and technical, which were identified by the reviewers. Further, the establishment of causality is somewhat lacking.

We are pleased the reviewers as well as the editors found our work to be of interest and are grateful for their constructive comments for improving the manuscript. As the editors can appreciate, we have made abundant changes in the manuscript guided by the reviewers' points and requests. Specifically, we have removed several panels and included sub-sections related to the integrated systems biology analysis in order to simplify the message.

Additionally, to remove the word "hijacking" as instructed by reviewer \#4, we have now changed the title of the manuscript to "Anevolutionary recent IFN-IL6-CEBPB axis is linked to monocyte expansion and tuberculosis severity in humans".

Finally, while the in vivo evidence presented in the manuscript is indeed based upon association and correlation, rather than causality, as is inherent to human studies and evolutionary experiments (Karmon and Pilpel, 2016), we have now presented novel data containing mechanistic insights to underscore our research hypothesis, as instructed by reviewer \#4.

> Reviewer \#1:
>
> Background: M. tuberculosis has been detected in the bone marrow -- suggestive of a possible niche for tubercle bacteria in active and latent TB. This observation also points towards a role for mycobacteria in driving differentiation of certain cell types from Hematopoietic stem cells (HSCs).
>
> Key findings include:
>
> 1\) The demonstration of the ability of tubercle bacteria to replicate in Hematopoietic stem cell progenitors (HSCPs), in this case CD14^+^ and CD34^+^ cells.
>
> 2\) Transcriptional analysis of infected CD13+ cells indicated that M. tuberculosis infection drives these cells towards myeloid differentiation, further confirmed by flow cytometry. This observation was confirmed with cells from cord blood also.
>
> 3\) A role for IL6R was confirmed in this myeloid differentiation pathway, using a neutralizing antibody.
>
> 4\) By interrogating transcriptome data, the authors confirm that the IL6R-CEBP pathway is central in monocyte expansion.
>
> 5\) Comparative genomics and evolutionary analysis reveal that this pathway has been the subject of recent selection.

We thank the reviewer for his/her analysis of our manuscript and for the positive comments on our manuscript.

> Major Concerns:
>
> 1\) Figure 1---figure supplement 1C is meant to indicate that low numbers of bacteria associate with CD34^+^ cells. However, there is no comparison with CD14^+^, no quantification no statistics. This figure does not have use as it stands. Similarly, with Figure 1---figure supplement 1D -- one assumes the control here would be uninfected cells? In this case, the statistical comparison shown is meaningless -- comparing the bacterial load in CD14^+^ cells versus CD34^+^ cells on one graph would be more useful. The authors indicate they are comparable -- but need to provide the data in a way that allows for this comparison.

We apologize for the unclear information provided. The set of experiments to study *Mtb* infectivity by CD34^+^ cells employed two approaches. First (Figure 1A-D), we used PBMC cultures, which contain both CD14^+^ and CD34^+^ cells in the same well. Second (Figure 1E-G and Figure 1---figure supplement 1C,D), we used sorted cord blood derived purified CD34^+^ cells and PBMC derived purified CD14^+^ cells from different subjects. Hence, employing confocal microscopy, now Figure 1---figure supplement 1C was meant to formally demonstrate that purified CD34^+^ cells can be infected by *Mtb*. In contrast, novel Figure 1---figure supplement 1D was meant to be a positive control confirming that H37RV *Mtb* replicates in purified CD14^+^ cells and, in that case, the statistical comparison was performed to show that the bacilli replicate over time. We apologize for the unclear information provided and have now clarified this information in the Results section and included a representative dot plot of the CD14^+^ cell population in Figure 1A.

Additionally, while we observed a statistical difference between *Mtb* replication in CD34^+^ vs CD14^+^ cells, we have not included this information in the same graph because these cells were not obtained "side-by-side" from the same donors and these cell populations were cultivated in different media -- purified CD34^+^ cells require complete StemSpan SFEM II (growth factors enriched media, please see Materials and methods). Nevertheless, for comparisons and as per reviewer's request, we have now presented this new information below ([Author response image 1](#respfig1){ref-type="fig"}, left panel). As expected, we have observed that CD14^+^ cells, which are known to be highly phagocytic cells, are permissive to *Mtb* H37Rv infection. Importantly, purified CD34^+^ cells sustain H37Rv proliferation in vitro.

![Comparative Mtb growth in purified CD14+ vs CD34+ cells.\
Left panel, *Mtb* growth curve in sorted purified CD34^+^ or CD14^+^ cell cultures. Right panel, *Mtb* growth curve of sorted purified CD14^+^ cells cultivated in RPMI vs StemSpan SFEM II media.](elife-47013-resp-fig1){#respfig1}

As a control (for the reviewer's benefit), we observed that H37Rv *Mtb* growth is similar in CD14^+^ cells cultivated in complete StemSpan SFEM II media or regular RPMI media ([Author response image 1](#respfig1){ref-type="fig"}, right panel) suggesting that this commercial media does not interfere with *Mtb* replication, and thus the *Mtb* growth curve as shown in [Author response image 1](#respfig1){ref-type="fig"} (left panel) is a consequence of the intracellular replication in each cell population. While direct comparisons between CD34^+^ vs CD14^+^ cells are difficult to approach, our data corroborate that CD34^+^ cells are permissive to *Mtb* H37Rv infection in vitro. Thus, we have now re-written this section and clarified this point in the Results section as a novel supplement to figure 1 (Figure 1---figure supplement 1D).

> 2\) Figures 1 F and G need quantification, followed by statistical comparison.

Thank you for the suggestion. Quantification has been included as per reviewer's request. The data confirms the% of infected cells at day 1 and 5 p.i. as well as the higher% of cytoplasm richer cells in *Mtb* vs uninfected cell cultures. These panels have now been incorporated in new Figure 1 and in the Results section.

> 3\) Figure 2---figure supplement 1B and C needs statistics, are the differences significant, if not the text needs to be revised to indicate this. This applies to all supplementary graphs, these should have statistics. If differences are not significant \"NS\" should be stated. Same with Figures in the main text.

All graphs are now supplied with statistics. "n.s" was used for all tests in which the p value was higher than 0.05. In a few cases, such as those where found an inherent biological variation of human samples, we included the exact p values. We have also included an excel table with statistical information from each graph present in the manuscript to further clarify this section (Supplementary File 4).

> 4\) The comparative genomics/transcriptomics and evolutionary analysis is very dense, it needs to be simplified and presented in a clearer manner.

We acknowledge the reviewer's suggestion and we have made numerous alterations in the manuscript to present the information clearer. Specifically, we have transferred a large part of the data to the supplementary section and have removed several panels from Figures 5 and 6.

However, in reply to reviewer\#4 (detailed below) regarding the 'indirect nature' of our data, we have also added two additional panels (Figure 6C: Chipseq analysis, chromatin architecture and CD34^+^ vs CD14^+^ cell RNAseq data; Figure 6E: increased transcription of *Mtb*-induced genes in matched European vs. African descendants with documented Neanderthal introgression), which provide solid experimental support for our hypothesis.

Overall, although our integrated system biology analysis is based on a large body of data (transcriptomics, proteomics, genomics and functional assays), we have now streamlined the evolutionary analysis into a stepwise story. Following the evolutionary timeline from early mammalian emergence (\>100 million years ago (mya)), over primate (\>50 mya), and hominid evolution (\>15 mya), recent human evolution including Neanderthal introgression (\<100,000 years ago) and human pathogen adaptation (15,000-1,500 years ago), up to extant human genetic variation (large GWAS studies). We have also added the specific timelines to each relevant panel of Figure 6 and 7, so we hope the reviewer will appreciate that the data 'flow' is indeed more simplified and the text easier to read.

> Reviewer \#2:
>
> In this manuscript Delgobo et al. demonstrate a novel role for Mtb in driving monocyte differentiation from human hematopoietic stem cells via an IL-6/CEBP axis. In vitro studies show that Mtb replicates in human CD34^+^ cells, and causes upregulation of the monocyte marker CD14 as well as enrichment of genes associated with myeloid differentiation. This in vitro monocyte expansion is demonstrated to be IL-6 dependent and associated with STAT1 and CEBP signaling. IL-6 receptor blockade impairs CD14 upregulation in infected CD34^+^ cell and reduces CFU burden, suggesting that this differentiation pathway is advantageous for Mtb. Interestingly, analysis of the IL6/IL6R/CEBP signaling axis among different mammalian species suggested that coordinate regulation of CEBP by IL6 and type 1 IFN is a relatively recent event in mammalian evolution and seems restricted to primates. This is corroborated by in vitro experiments using infection of cells from 10 species. Overall, the authors demonstrate, with compelling mechanistic evidence, a role for Mtb in co-opting an evolutionarily recent signaling axis to support infection by driving monocyte differentiation. The evolutionary aspect of the study is particularly intriguing.

We appreciate the reviewer's analysis of our manuscript and thank him for his positive comments on the manuscript.

> Reviewer \#3:
>
> In this manuscript the authors\' study the mechanisms by which HSPC differentiation occurs following Mtb infection. The authors uncover a less studied role for IL-6/IL-6R signaling in driving HSPC commitment to myeloid differentiation and exacerbating TB disease. In particular, re-analysis of previously published transcriptomic, proteomic, and genetic datasets support their hypotheses. Addressing the below points will further improve the impact of the findings.

We thank this reviewer for his/her positive comments on our manuscript and are grateful for his/her suggestions.

> Major comments:
>
> Figure 1B-D:
>
> The authors show that approximately 60% of CD34^+^ cells stain positively for Mtb with syto24, but that each of these cells has a much lower Mtb syto24 MFI than similarly infected CD14^+^ cells. However, after 4h, both CD34^+^ and CD14^+^ cells have a very similar number of CFU/ml.
>
> Is the rate of uptake/infectivity potentially different when the cells are isolated and infected in a homogeneous culture rather than infected as total PBMCs?
>
> It would also be useful to see the uninfected control quantified and included in the flow analysis as well.

This is an interesting point. While Syto24 is a fluorescent probe employed to detect the frequency of Syto24-positive CD34^+^ vs CD14^+^ PBMC populations in the same well, this technique yields only an estimate of the numbers of *Mtb* associating with the host cell. Therefore, CFU/ml was used as a reliable golden standard bacterial count. To assess the reviewer's question, we would need to isolate CD34^+^ cells and CD14^+^ cells from PBMC, infect with *Mtb*Syto24 and compare to CD34^+^ and CD14^+^ cells sorted from *Mtb*Syto24-infected PBMCs. This would allow us to measure side-by-side the ratio of infectivity/uptake of *Mtb* by these two cell populations from the same donors. Unfortunately, we do not have access to cell sorting equipment in our BSL-3 facility and are unable to sort *Mtb*-infected cells. Nevertheless, we have compared the *Mtb*Syto24 frequency of CD34^+^ PBMC versus purified cord blood CD34^+^ cells and found similar frequencies and MFI numbers by these cells at 4h. These data support that the rate of uptake/infectivity of CD34^+^ cells is not different when isolated or infected as (a small fraction of) total PBMCs. We have now incorporated this information in the Results section (new Figure 1---figure supplement 1B) and, as per reviewer's request, we have now included the uninfected control in the flow cytometry analysis (new Figure 1D).

> Figure 3:
>
> The authors show that heat-killed Mtb is unable to stimulate the same increase in myeloid differentiation of CD34^+^ cells as live Mtb. However, they later show that it is a cytokine (IL-6) dependent phenomenon. Are the IL-6 levels induced by heat-killed Mtb significantly lower than live infection?

The reviewer raises an interesting point but we need to correct that, based on the experimental approach employed and its limitations, in our original version of the manuscript, we have stated that *Mtb* enhanced myeloid differentiation in CD34^+^ cells by an IL-6R-mediated process. Since many myeloid differentiation markers were blocked by neutralization of IL-6R signaling in both untreated and *Mtb*-exposed cell culture systems, we deduced that this was an IL-6R-'mediated' and not IL-6R-'dependent' phenomenon. Nevertheless, as per reviewer's request, we have now measured intracellular IL-6 levels in CD34^+^ from PBMC exposed to HK *Mtb* and live *Mtb*. Interestingly, both live Mtb and HK *Mtb* stimulates production of IL-6 as measured by flow cytometric intracellular staining ([Author response image 2](#respfig2){ref-type="fig"}).

![PBMC cultures were exposed to Mtb H37Rv (MOI=3), HK Mtb or LPS (100 ng/mL) for 24h and intracellular IL-6 was detected by flow cytometry.\
Live CD34^+^Lin^-^ events gated as in Figure 1A were analyzed for IL-6 MFI.](elife-47013-resp-fig2){#respfig2}

Nevertheless, such increased levels of IL-6 found in HK *Mtb* appeared not to be sufficient to induce full myeloid differentiation as seen in the live infection samples. As shown in Figure 7---figure supplement 1, HK *Mtb* does not enhance known myeloid differentiation surface markers CD4, CD64 and CD38 by progenitor CD34^+^ cells as seen in cultures exposed to live infection.

This evidence suggests that unknown activities of live pathogen infection regulates myeloid differentiation involving an IL-6R-mediated process and implies cross talking of regulatory pathways between live *Mtb*, IL-6 and interferon signaling to boost myeloid differentiation of CD34^+^ cells. While live *Mtb* strongly induces ISGs, inactivated (HK) mycobacteria do not, as seen in this study for CD34^+^ cells and others for human macrophages (Novikov et al., 2011) Additionally, *CEBPB*, a major regulator of myeloid differentiation, was not induced by HK *Mtb* but it was highly induced by live *Mtb* infection and only slightly by recombinant IL-6 treatment.

We believe live *Mtb* is a very potent stimulus to enhance STAT1 downstream pathways and ISG expression, and at least part of its actions involves an IL-6-C/EBP-β feed-forward loop in vitro. Our data suggest a collaborative and, for some functions, a redundant role for IL-6 and IFNs, C/EBP-β being an important hub for myeloid differentiation. While it has been reported that IFN-induced C/EBP-β activates GATE sequences independent of STAT1 in certain cell lineages (Li, Gade, Xiao, and Kalvakolanu, 2007), the mechanisms through which endogenous IL-6, IFN-α/β and live *Mtb* interplay to induce myeloid differentiation of HSPCs will require further exploration. We have now incorporated this data as new figures (Figure 4C and Figure 4---figure supplement 1F,G) and have included these points in the Results and Discussion section.

> Figure 4:
>
> Cytokine signaling is a known trigger for myeloid cell differentiation, and therefore the authors identify differential expression of IL-6 as a potential driver of the increased number of CD14^+^ cells induced by Mtb infection. However, despite seeing what appears to be a significant transcriptional increase of IL-6 at 5dpi, there is no correlating increase in protein at that time point. CD34^+^ cells infected with Mtb and treated with aIL6R for 10d develop a lower percentage of CD14^+^ cells than untreated infected cells, at a much later time point than when differences in IL-6 induction (either by protein or transcriptional data) are seen.
>
> A time course showing IL-6 levels in culture (1,3,5,7,10dpi) as well as a time course showing when the CD14^+^ population begins to expand in the untreated Mtb infected cells would more support the idea that it is an IL-6-dependent expansion. Alternatively, the authors could consider only blocking IL-6R early, when there is a significant difference in protein levels, to determine if there is the same effect on myeloid expansion.

The reviewer raises an interesting point. The RNAseq data demonstrated in the heat maps were displayed as z-score values. However, when we plotted RNAseq normalized counts data from 2 independent experiments (technical replicates from 3 donors), we can observe that *IL6* (and *IL6R*) transcript levels are higher in *Mtb*-exposed cultures than those found in uninfected cells starting at day 1.

This was confirmed by qPCR experiments (novel Figure 4---figure supplement 1B,C), which showed enhancement of *IL6* amplification at day 1 post-infection, thus correlating with the protein being produced at this time point. However, we only started to detect a measurable difference in monocyte frequencies at 5-7 dpi. This is consistent with the idea that early signals, such as those provided by IL-6/IL-6R, are important for driving CD14^+^ monocyte differentiation at later time points. In agreement with this hypothesis, it has been reported that IL-6 increases myeloid output in multipotent progenitors but not in lineage committed myeloid progenitors (Schurch, Riether, and Ochsenbein, 2014), which implies several sequential cellular or molecular processes are needed for monocyte development to be completed. As per reviewer's request, we have performed a detailed time course to measure CD14^+^ frequencies during *Mtb* infection by CD34^+^ cells. As a control, we confirmed that *Mtb* H37Rv replicated in the cultures over time ([Author response image 3](#respfig3){ref-type="fig"}). Furthermore, CD14^+^ monocytes started to appear on day 3 of culture, but only at day 7, *Mtb* shows a slight difference in terms of CD14^+^ levels. This difference becomes more evident by day 10 of culture.

![Mtb growth and CD14+ frequencies in CD34+ cultures exposed to H37Rv in vitro.\
Left panel, CFU loads of human cord blood purified CD34^+^ cells infected with Mtb H37Rv. Right panel, frequency of CD14^+^ cells in uninfected vs *Mtb* infected CD34^+^ cells over time.](elife-47013-resp-fig3){#respfig3}

It has been previously reported that early signals are sufficient to drive CD34^+^ cell differentiation (Rieger, Hoppe, Smejkal, Eitelhuber, and Schroeder, 2009; Sarrazin et al., 2009). In the published model, specific transcription factors (TFs) need to be sequentially activated to stimulate cell differentiation processes. Indeed, when we employed Cell Router on 180 hematopoiesis-associated TFs found in our transcriptomics (Figure 2B), we observed that mRNA signature scores for the myeloid development (GRAN/MONO) started at day 1 post-infection, but a difference between untreated vs *Mtb*-exposed cells was detected only after day 3 of infection. Thus, our data suggest a model in which exogenous IL-6 (in the conditioned StepSpan medium) primes secretion of endogenously produced IL-6 by live *Mtb* at day 1, which sequentially activates myeloid TFs and their targets on the following days of culture, culminating with measurable CD14^+^ cells at later time points.

However, at later time points, cell cultures change by displaying increased cell heterogeneity in addition to *Mtb* replication, which makes it difficult to approach how IL-6 responses are regulated. For example, in experiments using exogenous IL-6 (20 ng/mL) and *Mtb*, we observed that simultaneous addition of both downregulated C/EBP-β protein levels (Figure 4---figure supplement 1, compare 3^rd^ and 4^th^ lanes). It appears that, while a certain level of IL-6 production is enhanced by *Mtb*, too much cytokine could have some inhibitory actions, indicating a very complex interplay between IL-6 and *Mtb* infection. We believe that, in addition to IL-6-mediated myeloid differentiation by *Mtb* initiated early on during infection, pathogen replication regulates yet-to-be-defined intracellular associated events. We appreciate the reviewer's suggestion about the early blockade of IL-6, but unfortunately, we did not have enough cells to perform this experiment. Nevertheless, our data show that IL-6R participates in the *Mtb*-enhanced myeloid differentiation and we have now incorporated the monocyte differentiation curve data (Figure 3---figure supplement 1E) in the Results section.

> Additionally, despite making note that \"interferon signaling\" and \"interferon alpha/beta\" pathways were significantly enriched in the infecting cells, neither IFNa/b nor IFN-g are well represented in the RNAseq data that is shown, and these cytokines are also not measured at the protein level. Including this data would provide better support for the data represented in Figure 4D-E, where no changes are seen after IFNAR or IFN-g blockade. This is a particularly critical point for the authors\' later argument that transcription factors induced by both IFN and IL-6 are primarily being driven by IL-6 to induce myeloid differentiation.

We were also intrigued with the increased ISG expression in the RNAseq without IFN-α/β and IFN-γ being represented in the RNAseq data. However, some but not all donors displayed increased *IFN* mRNA as detected in qPCR experiments (Figure novel S4c), which could partially explain the observed \"interferon signaling\" and \"interferon α/β\" pathways enriched in our samples. However, several groups previously demonstrated that while ISG expression can be easily detected, *IFNA/B* mRNA or protein are notoriously difficult to detect (Berry et al., 2010; Rodero et al., 2017). For example, a recent study (Llibre et al., 2019) employed digital ELISA to show neither type I IFN was detected in samples from tuberculosis patients, whereas type I IFN signaling is detectable in myeloid cells after infection (Berry et al., 2010). Nevertheless, as per reviewer request, we measured IFN-γ in the supernatants by ELISA, which showed no production of this cytokine in CD34^+^ cell cultures exposed to *Mtb*. Unfortunately, we did not have access to the ultrasensitive assay used by Rodero et al. and Llibre et al. to measure type I IFNs. However, anticipating the difficult to measure type I IFN in our system, we have performed experiments blocking IFNAR2, demonstrating inhibition of *Mtb*-enhanced ISGs STAT1 and MX1, suggesting bioactive type I IFN protein is present in our system and involved in the ISGs transcription upregulated in CD34^+^ cells. We have now included this new set of data in a new Figure 4---figure supplement 1(E and H) and have mentioned this in the Results section of the manuscript.

> The authors show in Figure 1 F-G that Mtb is associated with cells undergoing morphological change. If exogenous IL-6 alone is sufficient to drive this myeloid differentiation, why would the cells actively infected with Mtb be the only cells showing signs of differentiation? The authors may want to consider additional discussion of this point.

We thank the reviewer for raising this point. We also observed cytoplasm-richer cells in the uninfected cultures, albeit at lower numbers when compared to *Mtb*-exposed cells. Originally, we intended to show that *Mtb* enhances cellular differentiation when compared to uninfected cell cultures. As per request of reviewer \#1, we have included quantification of "signs of differentiation" in the Results section (Figure 1F-G). We apologize for the lack of clarity and as per reviewer's request we have now clarified this point in the Results section.

> Reviewer \#4:
>
> This manuscript investigates relationships (in human cells) between tuberculosis infection, hematopoiesis and monocyte expansion, and IL-6 signaling. In many respects the authors are investigating an aspect of \'trained\' immunity or myeloid lineage \'remodeling\' in the bone marrow. There are many substantial problems with this manuscript; the main one being an emphasis on correlation rather than causation. The authors attempt to draw conclusions that are predominantly indirect in nature.

We acknowledge this reviewer for his/her comments on our manuscript and have addressed the topic of correlation vs. causation, as well as the length of the evolutionary analysis. While we did not indicate in the paper our findings were "causal", we have made many substantial changes in the manuscript which now provide further mechanistic insights and additional experimental supporting a role for the IFN-IL6-CEBP gene module in TB susceptibility connected to myeloid differentiation.

Though the reviewer's comment that we are investigating of *"an aspect of trained immunity or myeloid lineage remodeling*'" could be a possibility, based on our study, we cannot conclude that the Mtb-activated IFN-IL6-CEBP gene module directly induces *de facto* innate immune memory (Netea et al., 2016) in vivo. To do so, we would need to investigate cohorts of re-infected patients and interrogate whether the IFN-IL6-CEBP axis is modulated during re-infection and linked to different TB disease outcomes. Unfortunately, to our knowledge, no such cohorts exist at the present moment and the correlates of innate immune memory during the natural infection of *Mtb* are still an open question in the field. Yet, our results argue in favor of the IFN-IL6-CEBP axis amplifying, rather than protecting against TB disease in humans. In support of this hypothesis, HSPC-derived monocytes induced by *Mtb* display increased frequency of CD14^+^CD16^+^ cells (Figure 3J), a subpopulation associated with severe TB disease (Balboa et al., 2011).

> 1\) That CD34^+^ cells can be infected in vitro does not mean it happens in vivo. The authors draw from other studies that argue that M.tb can get to the bone marrow. However, overall, there is no evidence that CD34^+^ cells are infected in vivo and if this would make any difference to myeloid output.

We respectfully disagree with the reviewer since it has been previously demonstrated that CD34^+^ cells are indeed infected with *Mtb* in vivo in humans. We have cited these studies in the original version of the manuscript (Tornack et al., 2017). In addition, as summarized in Mert et al. (Mert et al., 2001), 39 out of 149 bone marrow biopsies in 6 case series of miliary TB patients were positive for *Mtb*, by Ziehl-Neelsen staining and/or PCR. It should be stated that the samples used in their study were either obtained at autopsy or for diagnostic purpose. Due to obvious ethical limitations, we did not have access to bone marrow samples from patients with active TB, but have compared our results obtained in CD34^+^ cells obtained from purified cord blood and PBMCs with CD34^+^ cells from healthy bone marrow, with similar results (novel Figure 2---figure supplement 1B,C). Regarding myeloid output in TB, we have also cited early studies showing that monocytes are increased in active pulmonary TB patients (Rogers, 1928; Schmitt, Meuret, and Stix, 1977). Furthermore, we have also cited more recent experiments by Scriba et al. (Scriba et al., 2017) demonstrating that monocytes are increased during activation of latent TB in vivo. Together, these studies provide a theoretical framework raising the possibility that *Mtb* infection enhances monocyte output during active TB disease in vivo. We have now stressed this point in the Introduction section of the manuscript.

> The authors ignore older studies in this area (Goodell\'s M. avium Nature paper, Murray et al. Blood on the IFN-gamma KO mice infected with BCG).

We did cite the work by Goodell and colleagues in our previous version of the manuscript (Baldridge, King, Boles, Weksberg, and Goodell, 2010). In this mouse model study, proliferation of HSPCs was induced by IFN-γ, whereas anti-IFN-gamma neutralizing antibody had no effect on monocyte expansion in our human HSPC model. While Murray, Young and Daley (1998) found a role for IFN-g in the extramedullary expansion of myeloid cells in BCG-infected mice, we did not detect production of IFN-γ in our supernatants of *Mtb* H37Rv-exposed human primary CD34^+^ cells. It should also be noted that mice infected with *M. avium, M. tuberculosis* or *M. bovis* BCG show different outcomes of disease such as cellular dynamics of myeloid cells circulating in the blood and/or recruited into the tissues. For instance, Noris and Ernst have recently reported *Mtb*-infected mice displayed increased egress of monocytes from the bone marrow to the blood (Norris and Ernst, 2018). In contrast, Baldridge et al. observed that, upon infection with *M. avium*, the absolute numbers of lymphocytes, neutrophils, monocytes, eosinophils and basophils in peripheral blood remained stable; with a relative increase of CD4^+^ T-cells and granulocytes. Moreover, Baldridge et al. showed a loss of granulocyte-monocyte progenitors, common myeloid progenitors, and macrophage-erythroid progenitors with a concomitant increase in common lymphoid progenitors in murine bone marrow. These changes are in strong contrast with human tuberculosis data, where several groups have demonstrated lymphopenia, in parallel to myeloid expansion (both granulocytes and monocytes), as discussed above in point \#1.1. We apologize for not citing previous work on murine models of BCG infection such as *Murray* et al. 1998, as our manuscript is focusing on human pathogenesis caused by *Mtb* infection. We have now cited the article by *Murray* et al. 1998 and in order to shorten and streamline the systems biology and evolutionary part of the manuscript, we have also removed data analysis of human BCG vaccination.

> 2\) Results section. The authors draw a conclusion \"These results suggest M.tb hijacks IL-6R-mediated myeloid differentiation by human CD34^+^ cells in vivo\". There is no evidence of \"hijacking\" provided. Only that something happens to the IL-6 pathway, which is entirely expected if a cell is infected with an intracellular bacteria.

We would like to correct that our manuscript actually stated: "These results suggest *Mtb* hijacks IL-6R-mediated myeloid differentiation by human CD34^+^ cells in vitro." We suggested the term "hijacking" because, in our opinion, this correctly and intuitively describes the in vitro process in which *Mtb* infection of purified CD34^+^ cells significantly increase monocyte expansion, resulting in significantly increased mycobacterial burden, both of which are blocked by anti-IL-6R antibody, the latter arguing in favor of causality, at least in vitro. However, as instructed by the Editor, we have now removed the word "hijacking" from the manuscript. We hypothesize this phenomenon might occur in vivo, since progression from latent to active TB is accompanied with increased monocyte levels (novel Figure 5F), significantly correlated with the IL-6 signaling pathway (novel Figure 5H-G-I, p\<0.0001), as well as in vivo *Mtb* loads in TB patients (novel Figure 5J*CEBPB* transcript levels versus *Mtb* sputum positivity, p\<0.01), all of this in paired samples (also expanded with disease severity measured as symptom count and modal X-ray grade in Suppl. Figure S5b). This in vivo evidence is indeed based upon association/correlation and we did not indicate causation in any of this data interpretation.

Weagree with the reviewer that IL-6 (among other pro-inflammatory cytokines) is frequently induced by upon infection by several bacteria. However, this does not translate into increased monocyte expansion in several murine models of infection. As outlined above, Baldridge et al. (2010) demonstrated strictly IFN-γ-dependent, IFNAR-independent HSPC proliferation upon *M. avium* infection, without any effect on circulating monocytes. On the other hand, MacNamara et al. described IFN-γ-dependent, IFNAR-independent monocytosis upon *Ehrlichia muris* infection (MacNamara et al., 2011). Boettcher and colleagues found G-CSF-dependent granulopoiesis upon LPS exposure and *E. coli* infection (Boettcher et al., 2014), while Granick et al. show PGE2-dependent granulopoiesis upon *S. aureus* infection (Granick et al., 2013). Since these models do not reflect physiological infection of the bone marrow, we have also compared *Mtb* with *Leishmania infantum*, which is a classical human bone marrow pathogen and the causative agent of human visceral leishmaniasis. As outlined above in reply to Reviewer\#2, we found that *L. infantum* infection of human CD34^+^ cells does not increase monocyte output in vitro, in contrast to *Mtb* infection. We have now clarified this point in the Discussion section.

> 3\) Subsection "Recent genetic changes link IL6/IL6R/CEBP axis, monocyte expansion and TB pathogenesis in humans". Myeloid expansion. In this very long section, the authors propose a correlation between myeloid expansion and M.tb infection, including a lengthy analysis of Neanderthal genomics, which cannot be tested.

As outlined in the reply to reviewer\#1, we have now streamlined the evolutionary analysis into a stepwise story. Following the evolutionary timeline from early mammalian emergence (\>100 million years ago (mya)), over primate (\>50 mya), and hominid evolution (\>15 mya), recent human evolution including Neanderthal introgression (\<100,000 years ago) and human pathogen adaptation (15,000-1,500 years ago), up to extant human genetic variation (large GWAS studies). We have also added the specific timelines to each relevant panel of Figure 6, so we hope the reviewer will appreciate that the data 'flow' is indeed more simplified and the text easier to read. In addition, we have removed a large part of data analysis from the text and also removed several panels from Figure 5 and 6.

Nevertheless, regarding "...*Neanderthal genomics, which cannot be tested*", we respectfully disagree with the reviewer. We have tested our evolutionary hypothesis on several independent levels, using a data-driven approach by integrating our findings in CD34^+^ cells with publicly available transcriptomic, genetic and functional genomic data generated by the scientific community. Starting with several datasets spanning mammalian evolution, we generated independent experimental confirmations providing strong evidence in favor of our observations: 1. amino acid conservation levels in IL6/IL6R/CEBPA/CEBPB/CEBPD*, 2.* human- and primate-specific IFN regulation of *CEBPB* and *CEBPD* transcripts as compared to other mammals or rodents (novel Figure 6A, Figure 6B-C and Figure 5---figure supplement 1D).

Regarding human genetics/evolution, of which Neandertal introgression analysis is a small (but significant) part (see below, novel Figure 6D), GWAS data validated in several independent cohorts from \>230,000 individuals (\>170,000 Europeans, \>62,000 Japanese) demonstrate an irrefutable genetic link between systemic monocyte levels and polymorphisms in several genes from our proposed IL6/IL6R/CEBP gene module (summarized in Figure 7A and detailed in Supplementary file 2), of which a significant number are also validated TB susceptibility genes (Suppl. Figure 5f). In the absence human "knock-out" models, GWAS of large case-control studies are the closest equivalent, several of which have been able to use Mendelian randomization to investigate causation (Porcu et al., 2019; Taylor et al., 2019; Warrington et al., 2019).

> In summary, the authors\' model may or may not happen. The reliance on correlative studies means no firm conclusions can be drawn about the system at hand. While some leeway is warranted because it is a human-based study, the overall conclusions are not sufficiently substantiated.

We respectfully disagree with the reviewer that we did not present substantiated evidence to propose this model (which has not been challenged by the other 3 reviewers). Nevertheless, we acknowledge his/her comment and have now included two new Figure panels, which provide mechanistic insights and additional experimental support for our model.

First, to substantiate our hypothesis that transcriptional up-regulation of *CEBPB* and *CEBPD* by IFN are recent in mammalian evolution, we compiled IFN signaling through STAT1 ChipSeq analysis with chromatin architecture, RNAseq gene transcription in purified CD34^+^ vs. CD14^+^ cells and sequence conservation across 100 vertebrates (ranging from birds to mammals). We compared the most diverse genes in our module, *CEBPB* and *CEBPD,* to the most conserved, *CXCL10* and *CXCL9*, with respect to their type I IFN regulation (represented in Figure 6B). As shown in Figure 6C, we found that STAT1-binding peaks in *CEBPB* and *CEBPD* observed by ChipSeq analysis of IFN-stimulated human monocytes corresponded to regions with active chromatin (DNase Hypersensitivity Sites, DHS) and correlated with increased downstream transcription in CD14^+^ monocytes and purified CD34^+^ cells. In agreement with our findings (represented in Figure 6B), only 3 out of 11 (27%) STAT1 binding peaks in *CEBPB* and *CEBPD* were found in regions conserved during mammalian evolution (from chicken to humans), while 6 out of 7 (86%) STAT1 peaks were conserved in *CXCL9* and *CXCL10* genes.
